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Summary 
 
 Amongst all the cellular signaling pathways, perhaps the most ubiquitous 
posttranslational modification used to regulate protein activity is protein 
phosphorylation. Aberrant regulation of the participants of the phosphoproteome 
network has been implicated in a number of cancer-related diseases, making them 
the second most important group of drug targets in medicinal research today. A 
major challenge in understanding protein phosphorylation is the sheer complexity of 
the phosphoproteome network based on the fact that precise timing and spatial 
aspects of protein phosphorylation are crucial to cell functioning.  
This thesis highlights on the small-molecule based chemical biology 
tools used to study protein phosphorylation. Chapter 1 focuses on the use of small-
molecule mimetics of phosphorylated amino acids and how their use has aided in the 
study of transient phosphorylation events with both spatial and temporal precision. 
The development of small-molecule biosensors and how it has in the last few years 
reached the stage where they may be deployed as viable alternatives to traditional 
protein-based biosensors will be discussed. The development of novel small-
molecule tools, such as kinase crosslinkers to identify upstream kinase that is 
currently untenable using traditional techniques will be highlighted. Finally, the use 
of small-molecules microarrays, high-throughput screening tool and high-throughput 
imaging that can be used to map out the complex network of the phosphoproteome 
will be discussed. These applications will be highlighted with novel strategies and 
designs of protein biosensor in the later chapters (Chapter 2 & 3) for the explicit 
understanding on protein localizations and its functions, with the hope to ultimately 
lead to protein substrate identification which could potentially serves as drug target 
appraisal. 
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The actions of various enzymes, substrates and ligands that build up a complex 
network of signals, feedback and modulation are known as cellular signaling pathways. 
Amongst all the cellular signaling pathways, protein phosphorylation is perhaps the most 
ubiquitous posttranslational modification used to regulate protein activity.
[1]
 Arguably 
one of the more well-studied signaling mechanism, phosphorylation is mediated by a 
duo of enzymes – kinases which are responsible for phosphorylation that initiates these 
signals, and phosphatases which are responsible for dephosphorylation that terminates 
these signals.
[2]
 Aberrant regulation of the participants of the  phosphoproteome network 
has been implicated in a number of cancer-related diseases, making them the second 
most important group of drug targets in medicinal research today.
[3] 
A major challenge in understanding protein phosphorylation is the sheer 
complexity of the phosphoproteome network. Almost 30% of all intracellular proteins 





 and hundreds of phosphoprotein binding domains.
[6]
 
Complicating the study of protein phosphorylation is the fact that precise timing and 
spatial aspects are crucial to cell functioning. While a decent understanding has been 
achieved through traditional biochemical and genetic-based methods,
[7]
 existing 
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techniques still fall short in addressing problems like clarifying the functional effects of 
specific phosphorylation events, relating cellular localization to kinase/phosphatase 
activity and investigating rapid kinetic changes.
[8]
 In the last decade, various synthetic 
molecule based chemical proteomic tools were developed and sophisticated application 
of these tools to study cellular phosphorylation events has provided exciting new 
insights into understanding of the phosphoproteome. 
The following section highlights the advances in the development of small-
molecule phospho-mimetics and its use in biological systems where substantial 
mechanistic insights have been gained. The novel concepts in the design of synthetic 
sensors and genetically encoded protein sensors allowing real-time reporting of 
phosphorylation events in vitro and in vivo and recent development of activity based 
proteomics profiling approaches for detecting phosphorylation and dephosphorylation 
activities from the proteome will be discussed. The use of small-molecule microarray as 
a high-throughput screening method to map out the complex interaction network of the 
phosphoproteome will also be described. Collectively, these studies demonstrate the 
utility of chemical proteomic tools in studying phosphoproteomics. These developments 
and concepts are broadly applicable to different biological systems and ongoing 
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1.2 Proteomics – An Overview  
The term “proteomics” is defined as the large-scale study of proteins, particularly 
in the investigation of their structures and functions.
[9, 10]
 Proteome is the set of protein 
expressed by an organism or system under defined conditions, at a given time. This also 
includes the modifications made to a particular set of proteins.
[11]
 Proteins are essential 
parts of living organisms serving as the main components of cells in physiological 
metabolic pathways. The complete sequence of the human genome in 2001 holds an 
extraordinary trove of information waiting to be further analyzed.
[12]
 However, the major 
challenge remained in systematically annotating all the functions, and characterizing the 
roles of genes from the astronomical sequence data. Besides, there are undeniable 
fundamental limitations in the study of gene functions at the prediction or transcriptional 
level. 
Proteomics is known as the extension of genomics study because it deals with the 
large-scale determination of gene and cellular function directly at the protein level. 
Compared to genomics study, proteomics provide a more elucidating understanding of 
an organism. First of all, the level of transcription of a gene is not equivalent to the level 
of expression into a protein. In the past, proteomics study was done by mRNA analysis. 
It is recently found that mRNA is not always translated into proteins.
[13]
  The protein 
content produced by mRNA depends largely on the respective gene it carries and the 
physiological state of the cell. Secondly, many transcripts produce multiple or defective 
proteins through alternative splicing or alternative post-translational modifications. 
Thirdly, many protein functions require the presence of interacting protein partners or 
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RNA molecules. Lastly, many proteins experience post-translational modifications that 
profoundly affect their activities.  
After translation, many proteins are also subjected to chemical modifications 
known as post-translational modifications, which are critical for protein functions. Such 
modifications include protein phosphorylation which occurs in many enzymes and 
structural proteins in the process of cell signaling. Besides, proteins are also subjected to 
modifications like glycosylation, acetylation, methylation, nitrosylation and oxidation. 
Some proteins are subjected to all of the modifications mentioned above, in a time-
dependent manner. This evidently illustrates the potential challenge in studying protein 
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1.3 The Role of Protein Phosphorylation  
Many of the “proteomic” studies focus on protein phosphorylation because of its 
functional participation in various cellular signaling pathways. Protein phosphorylation 
reaction involves the addition of a phosphate group to an organic compound. Protein 
phosphorylation plays a significant role in the complex cellular network via the 
activating and deactivating of many proteins. Protein kinases and protein phosphatases 
are involved in this reversible phosphorylation process, which induces conformational 
changes in the structure of many enzymes and receptors, causing them to become 
activated or deactivated.  





The hydrophobic portion of a protein can be turned into a polar and 
hydrophilic region through the addition of a phosphate (PO4
-
) molecule to the polar R 
group of an amino acid residue. This will induce a conformational change in the 
structure of the protein through the interaction of either hydrophobic or hydrophilic 
residues in the protein. The protein becomes dephosphorylated again upon deactivation.  
Protein phosphorylation is crucial for protein-protein interaction and protein 
degradation via "recognition domains." The many regulatory roles of phosphorylation 
include mediating enzyme inhibition and regulating biological thermodynamics 
reactions. Elucidating the complex cellular signaling network of phosphorylation events 
is known to be tedious as each and every protein affects one another in an intricate way. 
Global approaches combined with mass spectrometry-based proteomics have been 
applied to identify the dynamic changes of protein phosphorylation. Another approach is 
  6 
to map out the reoccurring patterns of interactive network by measuring the genetic 
interactions and identifying the respective targets of multiple proteins.
[15] 
Thousands of distinct protein phosphorylation sites exist in a given cell. It is 
estimated that one tenth to half of endogenous proteins are phosphorylated at the cellular 
level. A protein often contains multiple distinct phosphorylation sites (amino acids) 
which are responsible for the function or localization of that protein. Serine 
phosphorylation is one of the most common sites, followed by threonine 
phosphorylation. Phosphorylation of Tyrosine is relatively rare. The occurrences of 
histidine and aspartate phosphorylation are not common, but in some cases are involved 
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1.4 Small Molecule Chemical Biology Tools for Studying 
Cellular Phosphorylation Events in vivo 
1.4.1 Small-Molecule Mimetics of Phosphorylated Amino Acids 
 The elucidation of the phosphoproteome network requires new chemical tools 
that allow modulation of site-specific phosphorylation and dephosphorylation on a target 
protein, in both spatially and temporally controlled manner. Three types of 
phosphoamino acid mimics based on synthetic small molecules, namely the non-
hydrolyzable phosphoamino acids, caged phosphoamino acids and carboxyl-based, non-
hydrolyzable mimics, are most popular (Figure 1.1a). This section will focus on how 
these phosphoamino acids (pAA) mimics were site-specifically introduced into proteins, 
and how the resulting reagents were used to study protein phosphorylation and 
dephosphorylation. 
 Site-specific incorporation of pAA mimics into proteins is usually achieved with 
either protein semi-synthesis technology or nonsense suppression technology (Figure 
1.1b & 1.1c). In the case of semi-synthesis technology (Figure 1.1b), the pAA mimic is 
incorporated into a suitable peptide sequence using standard solid-phase peptide 
synthesis (SPPS). Subsequently, the peptide is ligated to the rest of the protein using a 
highly chemoselective coupling reaction best known as the native chemical ligation 
(NCL), which occurs between a peptide/protein having an N- terminal cysteine and a 
peptide/protein containing a C-terminal thioester.
[16]
 In the case of expressed protein 
ligation (EPL), intein-mediated splicing is used to produce a recombinant protein having 
  8 




 Using such protein semi-synthesis procedures, caged phosphoamino acids have 
been routinely incorporated into peptides and proteins, allowing spatial and temporal 
control over the release of a predetermined phosphorylation site in a target protein and 
the subsequent assessment of the role a particular phosphorylation/dephosphorylation 
event plays in real time. The caging group on these unnatural pAAs serves as a photo-
cleavable protecting group which masks the phosphate group from other proteins that 
might interact with it.
[18]
 Upon removal of the caging group by photolysis, the masked 
phosphorylated residue is exposed and hence becomes susceptible to phosphatases and 
PBDs. One representative example using such strategies were reported by Yaffe et al., 
where compound 4 (a caged pSer) (Figure 1.1a) was incorporated into a suitable 
phosphopeptide to study the role of 14-3-3 proteins (a well-known class of PBDs) in cell 
cycle.
[19]
 Upon UV irradiation and uncaging, the phosphopeptide displaced endogenous 
proteins from 14-3-3 binding, causing premature cell cycle entry. In another example, 
Hahn and Muir incorporated 4 into the MH2 domain of Smad2 using EPL and 
demonstrated that the nuclear localization of MH2 was affected by its phosphorylation 
state.
[20]
 Similar attempts were made by Becker et al. to incorporate compound 6 (a 
caged pTyr) in recombinant STAT6, and to use the resulting protein to demonstrate that 














 Figure 1.1 (a) Chemical structures of common phosphoamino acids (pAAs), their caged 
counterparts and most commonly used mimics. (b) Protein semi-synthesis technology 
using either the native chemical ligation (NCL) or expressed protein ligation (EPL) 
strategy. (c) Nonsense suppression technology for incorporation of pAA mimics into 
proteins 
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 Non-hydrolyzable pAA mimics are also widely used to study protein 
phosphorylation/dephosphorylation (Figure 1.1a). Among them, Pma (7) and Pfa (8) are 
used in place of pSer and/or pThr as their non-hydrolyzable counterparts.
[22]
 Site-
specific incorporation of these mimics has been shown to be a promising strategy for 
dissecting the function of protein phosphorylation on Ser/Thr residues. A classical 
example was reported by Cole and co-workers in 2003, in their study of Serotonin N-
acetyltransferase (arylalkylamine N-acetyltransferase, AANAT).
[23]
 An unnatural protein 
named AANAT-Pma31 was first semi-synthetically produced, using NCL, by ligating 
the C-terminal fragment of AANAT with an N-terminal synthetic peptide containing 7 at 
position 31.
[23a]
 Subsequent biochemical studies carried out with AANAT-Pma31 
unequivocally demonstrated the role of Thr
31
 phosphorylation in modulating AANAT 
cellular stability through 14-3-3 binding. Similar studies using 8 as a non-hydrolyzable 
replacement of pSer
205
 in AANAT further established the biological role of this residue 
in the function  of AANAT protein 
[23b]
. Finally, double incorporation of 8 at both 
positions 31 and 205 in AANAT revealed that doubly phosphorylated AANAT was able 
to bind 14-3-3 in a bivalent manner.
[23c]
 The use of non-hydrolyzable pAAs may also 
assist in computational modelling experiments and this has been demonstrated by Cole 
and co-workers in their studies of protein kinase A (PKA) to clarify the intramolecular 
auto-phosphorylation mechanism of this important kinase.
[24]
 Compound 9 (named 
Pmp), a non-hydrolyzable pTyr mimic, has been incorporated in peptides to generate 
potential inhibitors of protein tyrosine phosphatases (PTPs) due to this compound’s 
ability to withstand hydrolysis.
[25]
 However, a decrease in PTP-binding affinity was 
observed in the resulting peptide when compared to its pTyr-containing counterpart. 
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This has hampered its broad applications. Consequently, compound 10 (named F2Pmp) 
was developed, which was subsequently found to restore significant binding affinity to 
PTPs.
[26a]
 In a representative example, 10 was used by Cole and co-workers to study the 
function of C-terminal tyrosine phosphorylation in the regulation of SHP-1 and LMW-
PTP.
[26b] 
 Although the use of semi-synthetic protein synthesis to incorporate the 
aforementioned pAA mimics is a powerful method to obtain the desired unnatural 
protein, the strategy is most effective when the site of incorporation is near either 
terminus of the protein. Nonsense suppression technology developed by Schultz’s group 
made possible a major technical advance for site-specific incorporation of pAA mimics 
in any position within the protein, using both in vivo and cell-free systems.
[27]
 With the 
ability of genetically engineering unique tRNA/aminoacyl-tRNA synthetase pairs that 
allow the assembly of a variety of unnatural amino acids into a protein in response to an 
amber nonsense codon, this strategy has been enthusiastically adopted for the study of 
protein phosphorylation/dephosphorylation events. In one of the earliest examples using 
a cell-free system, Rothman et al. demonstrated the successful incorporation of caged 
pAAs (4, 5 and 6 in Figure 1.1) into proteins which were subsequently tested, upon 
uncaging by UV irradiation, to show native-like behavior in biochemical studies.
[28]
 In 
vivo-based, nonsense suppression approaches on the other hand require to-be-
incorporated pAA mimics to possess optimal cell permeability. Consequently, it is not 
yet possible to incorporate highly charged pAA mimics such as Pmp (9) or F2Pmp (10) 
directly, because of their poor cell permeability. pAA mimics based on carboxylic acid 
groups, e.g. 11-15, have been developed to bypass the use of the phosphate group in the 







known to possess superior 
cell permeability. A recent work by Schultz et al. nicely demonstrated the use of one 
such carboxylic acid-based mimic, 11, and its successful incorporation into recombinant 
STAT1 protein by utilizing a nonsense suppression system in E. coli.
[30]
 The resulting 
protein was able to dimerize and bind to DNA in a manner similar to the native pTyr
701
 
STAT1. Another excellent pTyr mimic (13), based on the non-hydrolyzable isoxazole 
carboxylic acid, was recently reported.
[31]
 Its incorporation into a known PPI (protein–
protein interaction) inhibitor named ISS610 of the STAT3 protein (an SH2 domain-
containing protein) produced a resultant compound which shows reasonable anti-STAT3 
activities, and at the same time possesses more desirable pharmacological properties. It 
remains to be seen, however, whether this pAA mimic can be successfully incorporated 
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1.4.2 Activity Based Probes for Protein Phosphatases and Kinases 
 The opposite actions of protein phosphatases and kinases dynamically modulate 
the phosphorylation state of a protein. This section discusses the use of activity-based 
probes (ABPs) for analyzing the functional states of protein phosphatases and kinases in 
a complex proteome, using a technique called activity-based protein profiling 
(ABPP).
[32]
 ABPs specifically label certain enzymes by covalent modification of the 
residues essential for the catalytic mechanism (Figure 1.2a). The labelled enzymes can 
be subsequently analyzed by in-gel fluorescence scanning, and where necessary, affinity 
pull-down/LCMS for target identification. ABPs usually consist of three key 
components: (1) a reactive group specifically targeting a subset of enzymes in an 
activity-based manner; (2) a reporter tag facilitating the identification and 
characterization of targeted proteins; and (3) a linker connecting the reactive group and 
reporter tag with an appropriate spacing. The design of early-generation ABPs for 
protein phosphatses and kinases were mostly based on potent and irreversible inhibitors 
of these enzymes.
[33a]
 One such example is AX7574 (16 in Figure 1.2b), which was 
synthesized by conjugation of a TAMRA fluorophore to the arginine side chain of 
microcystin-LR - an natural product and a known Ser/Thr phosphatase inhibitor that 
irreversibly modifies a non-catalytic cysteine in the active site of the enzyme.
[33b]
 For 
ABPs against PTPs, the very first probe developed was FMPP (17), which contains a 4-
fluoromethylphenyl phosphate moiety. The probe undergoes dephosphorylation by PTPs 
and forms an electrophilic quinone methide which can then irreversiblly react with 
nearby nucleophilic residues that present normally on the target enzyme.
[33c]
 Similar 
ABPs such as DFPP (18), which contains a 2-difluoromethyl phenyl phosphate, also 
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undergoes dephosphorylation, releasing a reactive intermediate and covalently labeling 
PTPs via a similar mechanism as 17.
[34]
 However, the diffusible nature of the reactive 
intermediates generated from both classes of probes leads to poor specificity and cross-
reactivity in the crude proteome, making these probes ill-suited for useful ABPP 
applications. Improved target selectivity with these probes was achieved by conjugating 
them to additional PTP substrate sequences.
[35]
 Another PTP probe developed by Zhang 
et al., 19, contains an -bromobenzylphosphonate group, which is a non-hydrolyzable 
pTyr mimic and sufficiently electrophilic to react covalently with the active-site cysteine 
residue in an PTP. Overall as an ABP targetting PTPs in a crude proteome, this probe 
was shown to be more specific than the earlier PTP probes, i.e. 17 and 18. However, the 
highly unstable nature of the probe renders it impractical for wide-spread applications in 
ABPP.
[36]
 Probes based on phenyl vinyl sulfone/sulfonates (20) are another class of PTP 
probes that were recently dveloped,
[37]
 but they are likely cross-reactive towards other 
classes of enzymes that also possess nucleophilic cysteine residues, i.e. cysteine 
proteases. In a most recent example, we developed peptide-based ABPs for PTP by 
incorporating a novel pTyr mimic, 2-FMPT (21), into suitable peptide sequences.
[38]
 
Apart from an additional 2-ﬂuoromethyl group located in the aromatic ring, 2-FMPT is 
structurally identical to pTyr and should cause minimal disruption in PTP recognition. 
The most signiﬁcant advantage of 2-FMPT over other existing PTP probes is that, with 
its N- and C-terminus (as in the case of naturally occurring amino acids), essential 
peptide recognition elements which occupy the proximal positions of pTyr in a naturally 
occurring PTP substrate could be introduced. Consequently, the corresponding peptide-
based probes were shown to achieve target-speciﬁc binding to/proﬁling of diﬀerent 
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PTPs. A further development of 2-FMPT resulted in a fluorogenic pTyr mimic based on 
a coumaryl amino acid, which was subsequently shown  to detect endogenous PTP 
activities in fluorescence-assisted cell sorting (FACS) and bioimaging experiments.
[39]
  
 More recently, we reported a new class of ﬂuorescently quenched activity-based 
probes (qABPs) which are highly modular, and can sensitively image (through multiple 
enzyme turnovers leading to ﬂuorescence signal ampliﬁcation) diﬀerent types of enzyme 
activities in live mammalian cells with good spatial and temporal resolution (Figure 
1.2c). We have also incorporated two-photon dyes into our modular probe design, 
enabling for the ﬁrst time activity-based, ﬂuorogenic two-photon imaging of enzyme 
activities.
[40]
 As shown in Figure 1.2C, these probes contained modular components, 
including an enzyme substrate warhead (WH), a fluorescence reporter and a quencher, 
strategically built around a mandelic acid core. The resulting fluorogenic probes were 
normally in the “off” state in which the reporter fluorescence was effectively quenched 
by the proximal dabcyl quencher. Upon introduction into cells and enzymatic cleavage 
of the WH, an 1,6-elimination reaction led to the release of the quencher group, 
liberating fluorescence and a quinone/quinolimine methide intermediate. Similar to 17, 
this reactive intermediate was able to form covalent adducts with nearby proteins in situ. 
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Figure 1.2 (a) Schematic representation of the ABPP strategy.  (b) Representative ABPs 







  17 
 Different types of kinase-targeting ABPs have thus far been developed, many of 
which take advantage of the presence of active-site nucleophilic residues such as 
cysteine or lysine (Figure 1.3). For example, Patricelli and co-workers reported a 
biotinylated derivative of the acyl phosphate ADP, 22, which was shown to react 
covalently with more than 400 kinases in the human proteome.
[41]
 In this case, the 
targeted kinases react with the probe irreversibly through a highly conserved lysine. 
However, this probe was also shown to react with many other nucleotide-binding non-
kinase proteins as well. The natural product Wortmannin is known to irreversibly inhibit 
phosphoinositide-3-kinases (PI-3Ks). By covalently conjugating Wortmannin to a 
TAMRA fluorophore, the corresponding probe AX7503 (23) was able to label not only 
PI-3Ks, but also Polo-like kinases including Plk1 and Plk3.
[33a,42] 
By using a 
bioinformatics-based approach, Taunton and co-workers designed and synthesized an 
irreversible RSK kinase inhibitor fmk,
[43]
 which was later converted to a RSK probe (24) 
with a clickable alkyne.
[44]
 By introducing a fluoromethylketone electrophile in fmk, this 
probe was designed to target the nucleophilic cysteine residue present in the ATP 
binding site of RSK. Instead of using known irreversible inhibitor scaffold for the probe 
development against kinases, one can also develop the so-called affinity-based probes 
(AfBPs) from reversible kinase inhibitors. This approach is potentially more appealing 
and powerful since many reversible inhibitors of kinases are available. A clickable 
kinase probe, 25, modified from the known kinase drug Imatinib™, was recently 
reported which was shown to covalently label Abelson tyrosine kinase (Abl) from a 
crude proteome.
[45a]
 The key components of this probe include a Imatinib core group 
which provides strong and specific binding to Abl kinase, and a benzophenone group, 
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which, upon UV irradiation, provides a covalent linkage between the probe and the 
kinase. The same concept was recently extended to the development of yet another 
kinase probe, a staurosporine-based AfBP, that shows robust labelling against a variety 
of kinases in the human kinome.
[45b]
 
 An innovative extension of the ABPP in kinase research was provided by Shokat 
and co-workers in their development of probes capable of cross-linking a target kinase 
and its substrates (Figure 1.3).
[46]
 In the original report, compound 26, which is an 
adenosine derivative containing an o-phthaldialdehyde (OPA), was used to successfully 
cross-link a kinase with its peptide-based pseudosubstrate.
[46]
 In the pseudosubstrate, a 
cysteine was introduced in place of the original residue located at the phosphorylation 
site of the peptide. During the cross-linking reaction, the conserved Lys residue from the 
kinase active site performs a nucleophilic attack on the dialdehyde group of OPA, 
triggering the formation of a stable isoindole linkage that covalently traps the kinase, the 
pseudosubstrate and 26 collectively. Unfortunately, 26 was shown to work only with 
recombinantly purified kinases, due to its high cross-reactivity. Subsequent 
improvements were made by replacement of the OPA group with naphthalene-2,3-
dialdehyde (NDA) and thiophene-2,3-dicarboxaldehyde, giving 27 and 28, 
respectively.
[47,48]
 The improved probes were able to cross-link kinase/pseudosubstrate 
complexes more efficiently in cell lysates. In an alternative approach that obviates the 
use of pseudosubstrates, Suwal and Pflum designed cross-linker (29), an ATP analogue 
with its γ-phosphate conjugated to a photo-crosslinker.[49] The kinase transfers the 
modified γ-phosphate to its substrate upon phosphorylation, and the photo-cross-linker 
on γ-phosphate captures the upstream protein kinase covalently upon UV irradiation. 
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Figure 1.3 Representative ABPs that target kinases and representative cross-linkers that 
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1.4.3 Synthetic Peptide-based Biosensors  
 Another major challenge in our understanding of phosphorylation events and its 
related signaling pathways is the lack of traditional methods to continuously measure 
kinase activities in a cellular environment that includes the presence of a large amount of 
related enzymes. In the last decade, synthetic peptide-based biosensors have emerged as 
powerful tools to measure phosphorylation events with good temporal resolution. This 
strategy also has the potential to be utilized for measurement of phosphorylation events 
in cells for live cell imaging when used in conjunction with microinjection or cell-
permeable peptide sequences. The most basic design for such peptide-based sensors is 
appending the small-molecule fluorophore to an optimized peptide substrate, although 
reports of chimeric peptide-protein biosensors have surfaced in recent years. Two major 
classes of synthetic biosensor designs have been developed extensively to date. 
Chelation-enhanced synthetic biosensors utilize a fluorophore that exhibit a change in 
fluorescent signal upon chelation to a metal cation, such as Mg2+ that is a co-factor 
involved in the kinase phosphorylation mechanism. The other design is the environment-
sensitive synthetic biosensors that utilize fluorophores which exhibit a change in 
fluorescent signal in response to a change in the polarity of its immediate environment, 
such as during a binding event when a hydrophilic solvent-exposed environment 
switches to a hydrophobic environment of the protein’s binding pocket. 
 The key advantage of using synthetic peptide-based biosensors is the relative 
ease in designing and tuning their spectroscopic properties to suit the purpose of the 
investigator, as it is arguably easier to synthesize and refine the design of a small 
molecule than to refine the design of an entire protein. In addition, while a twofold 
  21 
fluorescent signal change may be extremely challenging for protein biosensors, it can be 
routinely achieved using synthetic biosensors. This makes synthetic biosensors useful 
for sensing the activity of less-abundant endogenous kinases and for other high-
throughput screening applications. One major concern in the development of synthetic 
biosensors is that a peptide sequence may not accurately recapture the entire protein-
substrate binding event. For kinase biosensors this complication is also worsened by the 
fact that many kinases are known to be promiscuous and recognition of kinase-substrate 
interaction in some cases are achieved using extended recognition elements that involve 
residues located away from the phosphorylation site. Therefore, it has been suggested 
that such complications could hamper efforts to create a useable synthetic biosensor for 
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1.4.4 Chelation-Enhanced Biosensors 
 Prior to the early 2000s, small-molecule fluorophores produced a 
phoshorylation-induced change of about 20%, which was not sufficient to warrant their 
use over traditional FRET-based protein biosensors.
[50]
 The first successful attempt, 
which we define as having at least a twofold increase in fluorescent signal was reported 
by Lawrence and co-workers in 2002.
[51]
 In their work, the fluorophore design was 
adopted from Tsien and co-workers Ca2+ fluorescent indicator,
[52]
 and by appending it 
to a peptide substrate of Ca2+-dependent PKCα near the phosphorylation site, a Mg2+ 
receptor site comprising of the two carboxylates from the fluorophore and the newly 
introduced phosphate group (upon phosphorylation)  led to the production of a 140% 
increase in fluorescence intensity.
[51]
 In a conceptually similar design, Imperiali and co-
workers developed the sulfonamido-oxine (Sox) amino acid, which incorporates a 8-
hydroxy-5-(N,N-dimethylsulfonamido)-2-methylquinoline moiety that responds with a 
fluorescent signal change upon binding to a divalent metal cation (Figure 1.4a).
[53]
 
Compared with Lawrence’s work, the Sox amino acid was less bulky and had minimal 
interference with the recognition and reactivity with the kinase. By incorporating the 
Sox amino acid into a peptide sequence that served as a kinase recognition element, the 
resulting fluorescence increase upon phosphorylation spanned from 280% to 470%.
[54]
 
Considering that a 5-10% fluorescent signal change of the biosensor is typically 
measurable in most experiments, this means that synthetic biosensors are potentially 
sensitive enough to measure up to 1% turnover,
[55]
 making them suited for studying low 
kinase activity. 
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 It is evident that early work with synthetic biosensors had already demonstrated 
the routine ability to achieve fluorescent signal changes that span several folds as 
opposed to the incremental changes of less than 100% observed in most protein 
biosensors experiments. Issues with the specificity of such synthetic biosensors was 
addressed when Imperiali and co-workers validated their probes in an unfractionated cell 
lysate environment to be specific to Akt-1, PKA and MK2 kinases.
[56]
 The Sox-based 
peptide biosensor sensitivity was further improved by incorporating an additional 
proline recognition element to the turn sequence in the sensing module,
[57]
 and installing 
the Sox fluorophore onto a cysteine residue via alkylation (c-Sox), allowing Imperiali 
and co-workers to use both N and C-terminus recognition elements.
[55]
 The improved 
biosensor design led to the development of biosensors for a variety of representative 
Ser/Thr kinases, receptor and nonreceptor kinases with enhanced selectivity, up to 28-
fold improved catalytic efficiency and up to 66-fold lower km when compared to the 
earlier designs. While small-molecule peptide-based sensors enjoyed some degree of 
success, a number of physiologically important kinases, including ERK1/2 and other 
MAPK kinases do not derive their specificity from the residues flanking the 
phosphorylation site, but rather from extended recognition elements that include 
protein–protein interactions distal to the phosphorylation site. The development of C-
Sox allowed Imperiali and co-workers to incorporate it into a chimeric protein-peptide 
sensor for ERK1/2, in which the PNT domain component served as a recognition 
element (Figure 1.4b).
[58]
 The selectivity of the resulting Sox-PNT biosensor for ERK1/2 
was verified by immunodepletion experiments. This domain-docking approach was 
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further generalized with the design and validation of an isoform-selective p38 biosensor 
that was compatible with unfractionated cell lysate experiments.
[59]
 
 Finally, the rapid ease of synthesis of small-molecule peptide-based biosensors 
also allows investigators to rapidly design new specific kinase biosensors. This was 
demonstrated when Imperiali and co-workers developed a novel screening method that 
uses Matrix-assisted laser desorption/ionisation-time of flight (MADLI-TOF) mass 
spectrometry  to analyze the products of the target kinase acting on a peptide library to 
identify selective Sox-based fluorescent biosensors. This led to the discovery of an 
Aurora A kinase biosensor that showed a 7-fold improvement in catalytic efficiency 
over the best substrate described to date in the literature.
[60]
 The ease of using synthetic 
methods to tune a fluorophore’s spectroscopic properties was also demonstrated with the 
design of a “red-shifted Sox” fluorophore.[61] The application of this new fluorophore 
combined with the venerable Sox could potentially be used in designing synthetic 
biosensors for monitoring the activity of two different kinases, allowing investigators to 
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Designs of chelation enhanced biosensor: 
 
      a) 
  
 







Figure 1.4 (a) Chelation-enhanced fluorescence (CHEF) sensors based on Sox and c-
Sox unnatural amino acids. The key modules of fluorescent chemosensors of protein 
kinase activity include the critical kinase recognition elements, a chelation-enhanced 
fluorophore sulfonamido-oxine-CHEF Sox, and a β turn to preorganize Mg2+ binding 
between Sox and the introduced phosphate. Fluorescence signal is generated via the 
chelation of Mg2+, upon binding to the phosphorylated peptide. (b) The Sox-PNT 
sensor is synthesized using native chemical ligation method. PNT domain from Ets-
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1.4.5 Small-Molecule Environment-Sensitive Biosensors  
 One of the known drawbacks specific to chelation-enhanced biosensors is 
phosphoryl group competition with negatively charged groups like Asp/Glu residues and 
ATP during the binding process with the metal cation, which renders such biosensors 
potentially liable to be affected by the amino acid sequence of the target peptide and the 
ATP concentration. As a result, the use of environment-sensitive fluorophore in 
synthetic biosensors design may be advantageous. Environment-sensitive biosensors 
usually utilize fluorophores that exhibit a fluorescence signal change in response of an 
environmental solvent polarity change. Such solvent polarity changes can be caused by 
the introduction of a phosphoryl group near the fluorophore or by a binding event 
between a PBD (e.g. SH2 or 14-3-3) and a kinase substrate peptide upon 
phosphorylation. The former case was exemplified by an environment-sensitive 
fluorophore NBD, which produced a fluorescent signal change upon introduction of a 
phosphoryl group in close proximity (Figure 1.5a). NBD fluorophore conjugated with a 
PKC peptide substrate was capable of monitoring PKC activation in microinjection 
experiment.
[62]
 The latter case was exemplified by the using of environmentally sensitive 
fluorophore 32-34, which can be covalently attached to a tyrosine-containing substrate 
peptide.
[61]
 Upon phosphorylation, SH2 domain binds to the phosphorylated peptide and 
provides the hydrophobic environment, resulting in polarity changes that “turn on” these 
environmentally sensitive fluorophores (Figure 1.5a).  
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 In a “deep quench” strategy, a fluorophore quencher (35-37) was attached to the 
pyrene fluorophore in the peptide substrate non-covalently. Upon phosphorylation of the 
peptide substrate, PBD (e.g. 14-3-3τ) was recruited to isolate the quencher from the 
fluorophore, causing increase in fluorescence signal intensity (Figure 1.5b). In a PBD-
free approach, a fluorophore was quenched by the Tyr residue of the substrate peptide. 
Upon phosphorylation, the phosphate group disrupted the stacking interactions between 
the fluorophore and the Tyr moiety, causing an increase in the fluorescence signal.
[63]
 In 
another conceptually similar approach that utilizes a 14-3-3τ pSer binding domain that 
binds to the biosensor upon phosphorylation, thus sequestering the quencher from the 
fluorophore and restoring the fluorescent signal, the dynamic range of typical small-
molecule kinase biosensors was expanded to attain up to 50-fold change in fluorescent 
intensity.
[64]
 However, it remains to be seen if such biosensors that include the use of a 
secondary binding element can be successfully applied in vivo.  
 Interestingly, environment-sensitive biosensors have demonstrated their utility 
outside their traditional roles of bioimaging. Lawrence and co-workers adapted their 
PKC specific biosensor as a reporter in a stepwise combinatorial modification of a 
consensus sequence scaffold to generate a potent and selective PKC inhibitor that 
remains effective even at the high levels of ATP present in living cells.
[65]
 An added 
advantage of environment-sensitive biosensors is that it is not limited to studies at the 
binding pocket as is the case for chelation-enhanced biosensors that are inexplicably 
linked to the presence of the Mg2+ cofactor. Simard et. al. have taken advantage of this 
fact by attaching an environment-sensitive fluorophore near the allosteric site to develop 
a fluorescence-based kinase binding assay for identifying and characterizing ligands 
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which stabilize the inactive kinase conformation, which could potentially lead to the 
identification of novel allosteric inhibitors.
[66]
 
 Besides the two major classes of synthetic biosensors discussed, there still 
remain several novel fluorophore designs that respond specifically to phosphorylation 
events but do not fall clearly into either category. Lawrence and co-workers have 
utilized the quenching ability of Tyr residue to make a biosensor sensitive to Tyr 
phosphorylation, as the presence of a phosphate group disrupts the stacking interactions 
between the fluorophore and the Tyr moiety.
[67]
 A UV-sensitive caged version of the 
biosensor designs was delivered into human lung carcinoma cell line that expressed high 
levels of activated Src kinase by microinjection, and a time-dependent increase in 
fluorescent intensity was observed upon photolysis. In the design developed by Nagano 
and co-workers, a metal-center phosphate-sensitive sensor is attached to a fluorophore 




 In the last few years, we have seen an increasing number of applications of 
synthetic biosensors for in vivo studies, and it is worthwhile to note that the development 
of such tool is only a decade old. It is in the authors’ opinion that synthetic biosensors 
are just in their nascent stage of development and we are poised to see a growth of novel 
applications stemming from the use of synthetic biosensors in the near future. 
 
 






















Examples of small-molecule environment-sensitive biosensor: 
 
     a) 
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1.4.6 Genetically Encoded Protein Biosensors for Measurement of in 
vivo Phosphorylation Events 
 Although the aforementioned tools have provided precious insights into the 
function and regulation of phosphorylation, they all lack the ability to non-invasively 
and continuously track real-time dynamics of phosphorylation changes in a living 
cell.
[69]
 In recent years, genetically encoded protein biosensors have been developed for 
such purposes. Among them, the most widely used biosensors utilize changes in Förster 
resonance energy transfer (FRET) as readout for monitoring phosphorylation events. 
The most adopted modular design of such biosensors usually consists of a 
phosphorylation site sequence, a protein binding domain (PBD), a flexible linker in 
between and a fluorescent protein (FP) pair appended to N- and C- termini, flanking the 
above elements. Upon kinase action on the phosphorylation site, PBD binds to the 
phosphorylated residue and brings the FRET pair together into close proximity, leading 
to a FRET ratio change (Figure 1.6a). This was best demonstrated by the engineering 
work of the protein biosensor reporting PKA activity from Tsien’s group. Subsequent 
rounds of extensive optimization on phosphorylation site sequences, the choice of PBDs, 
linkers and FPs were done by Zhang’s group.[70] The latest protein biosensor exhibited a 
robust and reversible response after stimulation of PKA activity. Numerous biosensors 
with this design have been developed for both serine/threonine and tyrosine kinases.
[71]
 
Another key feature of these biosensors is the targetability of its subcellular localization 
via genetic insertion of unique amino acid targeting sequences. This location 
targetability allows it to reveal the spatial control of phosphorylation signalling regulated 
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by subcellular compartmentalization, commonly occurring in the plasma membrane, 
cytosol, nucleus and other organelles.
[72]
  
Kinase biosensors have been constructed utilizing alternative designs. For 
example, a FRET pair can be fused to a PBD and a kinase substrate protein, respectively 
(Figure 1.6a). In the study by Bastiaens’s group in 2004, YFP was fused to a 
phosphotyrosine-binding domain and CFP was fused to EGFR kinase.
[73]
 Upon 
treatment with its ligand, EGFR underwent auto-phosphorylation and subsequently 
induced the binding of the phosphotyrosine-binding domain, which triggered a rapid and 
reversible change in the YFP/CFP fluorescence emission ratio. In cases where the 
activation of a kinase itself generates a conformational change (e.g. CaMKII,ERK2, 
MAPK, etc.), a FRET pair could be tagged to its N- and C-terminus, respectively, to 
produce a kinase activity biosensor.
[74]
 Fragment complementation using a fluorescent 
protein or luciferase is another strategy used to induce a signal change upon 
phosphorylation (Figure 1.6b). For example, a phosphorylation-site sequence and the 
corresponding PBD could be appended to a circularly-permuted FP (cpFP), which was 
produced by breaking the backbone of the wild type FP and connecting its N- and C-
terminus.
[75]
 When phosphorylation occurred, the PBD caused an intramolecular 
conformational change which disrupted the complementation of cpFP, leading to its 
fluorescence decrease. Potentially, this strategy is compatible with monitoring multiple 
kinases; however, the dynamics of phosphorylation reported by decrease-of-intensity is 
less desirable. In a similar fashion, the complementation of a fragmented luciferase was 
used to report kinase activity using luminescence readouts.
[76]
 As reported by Herbst and 
co-workers, another complementation design, generalized for both FRET and 
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luminescence readouts, could significantly improve the dynamic range and sensitivity of 
detection in  native environments.
[77]
 
Although numerous types of biosensors were available to monitor kinase 
activities in living cells, very few are applicable to the study of phosphatases. For this 
purpose, an imaging approach was developed by Bastiean’s group to report the activity 
dynamics of phosphatases in living cells. In this approach, PTP1B was fused with a 
donor FP. A PTP1B substrate peptide was conjugated with an acceptor fluorophore 
(Figure 1.7a).
[78]
 The formation of PTP1B-substrate intermediate accompanied FRET 
ratio changes and reported the PTP1B activity. Interestingly, the Michaelis–Menten 
enzyme kinetics of PTP1B revealed a gradient of PTP1B activity across the cell, 
demonstrating the utility of this approach. Other non-FRET based alternatives recently 
developed for use in proteins included the use of bipartite tetracysteine display which 
was used to design a Src-family-kinase sensor that is both encodable and site-selective 
and it has demonstrated a higher fluorescent change than all but one of the reported 
FRET-based Src kinase sensors in the literature (Figure1.7b).
[79]
 We acknowledge that 
ongoing work in protein biosensors presents promising solutions to the known 
limitations of traditional FRET-based protein biosensors, and refer our readers to consult 
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Figure 1.6 Genetically encoded protein biosensors. (a) The Src reporter consists of a Src 
substrate peptide, the SH2 domain, a flexible linker, CFP and YFP. Upon 
phosphorylation by Src, the peptide substrate binds to the phospho-binding pocket of the 
SH2 domain, thereby generating intramolecular FRET signal. (b) The caged substrate 
peptide of PTP1B labeled with lissamine rhodamine B (LRh) binds to GFP-PTP1B 
















Figure 1.7 (a) A kinase-inducible bimolecular switch is generated by coupling the 
phosphoamino acid binding domain and the kinase substrate to the fragment 
complementation of the bioluminescent protein Renilla luciferase (RLuc). (b) In a non-
FRET based alternative, phosphorylation by a Src family kinase induces conformational 
change (step1) to LckSH2-p130Cas complex, thereby exposing four cysteine residues 
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1.4.7 Small-Molecule Microarray for High-Throughput Screening of 
Cellular Phosphorylation 
 Many of the techniques covered in this review thus far have focused on the use 
of small-molecule tools to supplement and enhance existing techniques in the field of 
traditional biochemistry and bioimaging for the study of phosphorylation 
/dephosphorylation events. In most cases, detail information of the target 
kinase/phosphatase and/or its potential substrates is known a priori. Despite the merit of 
such approaches, complementary high-throughput methods for studying cellular 
phosphorylation events without prior knowledge remain highly desirable. Of the various 
methods accessible to HTS applications, peptide and small molecule microarrays 
(SMMs) have emerged as one of the most powerful and versatile tools. These 
microarray platforms offer a variety of advantages over traditional screening methods, 
including miniaturization, parallelization and automated screening, allowing thousands 
of enzyme assays to be performed simultaneously.
[81]
 In line with the theme of this 
review, we focus primarily on peptide and small-molecule microarrays that have been 
used to enhance our knowledge of phosphorylation/dephosphorylation events. 
Specifically, we focus on microarrays that have been used to study phosphatases as well 
as PBDs. We will however not cover peptide arrays that have been extensively used to 




 In contrast to protein kinases, limited biological characterizations of protein 
phosphatases, in terms of their cellular partners and substrate specificities, are available. 
Waldmann and co-workers reported the first peptide microarray platform used in the 
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investigation of dephosphorylation events. A phosphotyrosine peptide microarray was 
used to map the in vitro substrate specificity of PTPμ and PTP1B, by monitoring the 
PTP activity via the loss of pTyr residue using fluorescently labeled anti-pTyr 
antibodies.
[84]
 The main drawback, however, is that it can only study PTPs due to the 
lack of reliable anti-pSer/Thr antibodies. In an independent study, we reported the first 
peptide microarray for high-throughput studies of Ser/Thr phosphatases. As shown in 
Figure 1.8 (workflow I), to detect peptide dephosphorylation on the glass slide, we used 
a signal-decrease assay with the commercially available Pro-Q Diamond dye, which is 
capable of fluorescence-based measurement of pSer/Thr/Tyr residues present in peptides 
and proteins.
[85]
 Compared to other microarray-based methods that report 
phosphorylation/dephosphorylation,
[82-84]
 the Pro-Q method is advantageous in terms of 
its safety, ease of handling, and sensitivity.
[86]
 With the ability to quantitatively 
determine multiple dephosphorylation events on the same microarray platform, our 
strategy has led to the new biological discovery that the dephosphorylation of the anti-
apoptotic protein Bcl-2, which plays a key role in apoptosis and cancer, is dependent 
upon the expression of peptidyl prolyl cis/trans isomerase Pin1.
[87]
 The same microarray 
platform was later found to be equally amenable to HTS of PTPs.
[88]
 Schweitzer and co-
workers independently verified that this peptide microarray approach, using Pro-Q dye 
as a detecting reagent, was comparable to standard solution-based assays.
[89]
 We recently 
extended this strategy by reporting what we called a fragment-based combinatorial 
peptide library consisting of 1000 different spotting features on a single glass slide 
(Figure 1.8; workflow II).
[90]
 With this new platform, a much larger peptide sequence 
space could be covered with a manageable number of spots/peptide libraries, without the 
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loss of detailed and subtle information on protein–peptide interactions. Subsequent high-
throughput screening was carried out to determine the substrate binding specificity of 
the highly homologous 14-3-3 proteins (a class of PBDs). To identify isoform-specific 
motifs amongst the seven 14-3-3 proteins, a dual-color ratiometric screening was 
adopted, using a protein mixture containing different 14-3-3 labeled separately by 
different dyes (i.e. Cy5 and Cy3).
[91]
  A novel putative binding motif of 14-3-3(one of 
the seven 14-3-3 isoforms) was eventually identified. 14-3-3 proteins are important 
PBDs in the cellular signaling pathways. They regulate several hundred proteins, many 
of which are important pharmaceutical targets. To date, only 14-3-3 has been linked to 
cancer through its direct interaction with p53 (a major tumor suppressor protein). 
Inactivation of 14-3-3 has been shown to be crucial in tumorigenesis. In our latest 
effort to discovery cell-permeable small molecules capable of binding to 14-3-3 
proteins, we developed a novel SMM, on which small molecule-peptide hybrid libraries 
(derived from our previously identified 14-3-3motif) were synthesized and screened 
against 14-3-3 (Figure 1.8; workflow III).[92] Eventually, a cell-permeable small 
molecule hit was identified which showed good cellular activities in disrupting protein-
protein interaction (PPI) against 14-3-3 proteins and their binder partners. 
 
  38 




























Figure 1.8 Schematic showing of key examples in the use of microarray platforms for 
high-throughput screening of cellular phosphorylation events. Three different types of 
workflows (I, II and III) have been developed, all of which involve steps of (1) 
compound library/array design, (2) array fabrication and functional screening, and (3) hit 
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1.5 High Throughput Imaging in System Biology 
The “post genome sequencing era,” has instrumented the identification of human 
genes and transcripts dispersed throughout the genome. The elucidation of the biological 
functions and interactions of all these genes and their products remained as the next 
major challenge. The determination of nucleotide sequence is insufficient to unravel the 
identification of gene’s encoded proteins in the cellular context. To address such a 
problem, Wiemann and group established a functional genomics and proteomics analysis 
pipeline by generating a human ORFeome resource (Figure 1.9).
 [93]
 By implementing 
bioinformatics tools for storage, analysis and integration of high-throughput experiments 
data, they created essential information for the complex biological network of genes and 
proteins including when and where genes are expressed, the localization, activity and 
interaction of the expressed protein. The identification of protein interacting substrate 
and the biochemical pathway is studied in hope to ultimately identify the potential drug 
target and relation to disease.  
 Like many of the present –Omic approaches; high-throughput imaging can 
provide insights to large scale biological network interactions, with spatial and temporal 
resolution. Imaging serves as an invaluable tool to approach biology as information 
science due to its unique capability to capture quantitative data with single cell 
resolution from intact living cells with minimum perturbation. With existence of 
automated instrumentation and advanced analysis tools, imaging becomes practical in 
probing biological circuit functions even via the large scale approach. Imaging provides 
less redundancy and pleiotropy that can mask important links compared to 
comprehensive approaches like gene sequencing and microarrays. Imaging offers single-
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cell resolution to analyze biological circuit functions at the single cell level. Different 
phenotypes of B. subtillis in microcolony is acquired and longitudinal analysis such as 
time-lapse imaging is made possible.
[94]
 Quantitative measurement of biological circuit 
is achieved by measuring the morphogens Bicoid and Caudal proteins, known to activate 
circuits differentially as a function of their concentration in fly embryo. High spatial 
resolutions of living cells are captured, while preserving the anatomical context of the 
living cells with improved subcellular resolution. This is important because many 
biochemical networks are linked by a few intercellular interactions.
[95]
  
Pepperkok and group developed a systematic and fast subcellular localization 
strategy by rapidly generating C- and N-terminal GFP fluorescent protein fusion of 
cDNA using a novel cloning system which allows rapid transfer of coding sequences 
between functional vectors. Using high- throughput automated imaging, intracellular 
localization of roughly 100 proteins are rapidly identified. As most protein functions are 
closely related to its localization, such techniques had provided the first hand in vivo 
data for further analysis, omitting the time consuming step in subsequent identification 
of localized cDNA.
[96]
 For further quantitative understanding of gene and biological 
network, Cohen and group examined the cell-cycle-dependence of nuclear proteins by 
measuring the changes in the amount and localization of proteins of individual cells, 
through synchrogram visualization using time-lapse microscope. To preserve wild type 
localization, nuclear proteins are CD tagged with YFP; in which the CD-cassette that 
provide slicing signal that direct inclusion of a new exon is inserted in an intron of a 
transcriptionally active gene in proper orientation. Translation of the tagged transcript 
results in the incorporation of the YFP tag into the protein. Cells are synchronized and 
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retroactively aligned based on nuclear fluorescence between consecutive cell divisions. 
This method allows the synchronization of each cell according to the cell cycle duration.  
They found that 40% of the nuclear proteins exhibited cell-cycle dependent dynamics.
[97]
 
Cohen and group took it one step further to examine the perturbation of proteome 
dynamics by studying the variability of human cancer cells’ response to the 
chemotherapy drug, Camptothecin. To preserve protein functionality, a library of over 
1200 cell clones is constructed using CD tagging method. Proteins exhibited rapid 
localization changes corresponding to the drug mode of action, accompanied by 
temporal changes in protein levels, as judged by changes in fluorescence intensity.
[98]
 
The rapid pace of development of chemical biology tools to study cellular 
phosphorylation events have only started to emerge in the last decade. The use of 
automated instrumentation and advanced analysis tools in high-throughput screening 
techniques has become practical for both high-throughput discovery science and 
hypothesis driven research. In hypothesis-driven research, multi-spectrum imaging can 
be used to monitor the spatial and temporal nodes of a biological circuit in real time. The 
powerful high-throughput imaging tools, standardized reporters and imaging conditions 
allow the present -Omic approaches to be achieved with improved resolution. 
 
To summarize, chemical biology tools for studying protein phosphorylation and 
dephosphorylation have experienced profound advancement in the last decade with 
improved performance in different applications. It will be interesting to see further 
developments of these tools to cover more members of the huge protein kinase and 
phosphatase family. Furthermore, general application of synthetic biosensor in living 
cell without using microinjection is another issue to be addressed. Nonetheless, to 
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understand how these kinases and phosphatases function under certain cellular condition 




Figure 1.9 Work flow for conducting high throughput (HT) imaging screen. 
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Chapter 2 
PTP1B-ABDF Substrate Trapping Mutant as Protein 




C-Src protein tyrosine kinase (PTK) is the first cellular homologue of retroviral 
v-Src. It can become a transforming protein when is over expressed in normal cells. It is 
found over expressed and highly activated in human cancer cells. The role of c-Src PTK 
kinase activation in relation to cancer made it a significant candidate to be studied. The 
activation of c-Src PTK is accompanied by the dephosphorylation of Tyrosine residue 
Y527 and the phosphorylation of Tyrosine residue Y416. However, the detail 
investigation on functional significance of c-Src PTK in normal biological circuits and 
in cancer cells remains a major challenge. The function of c-Src PTK is directly 
associated with its intrinsic activation, which is subjected to regulation in transforming 
cells. Therefore, the developments of new tools are necessary to monitor the dynamic 
activities of c-Src PTK within the physiologically relevant environment of cells.  
In this study, we aimed to meet this objective by designing an environmental 
sensitive protein biosensor using PTP1B labeled with a small fluorophore 4-Fluoro-7-
  44 
sulfamoylbenzofurazan (ABDF), and utilized it to study the activation and deactivation 
of c-Src PTK, via its ability to dephosphorylate both the residue Y416 and residue Y527 
of c-Src PTK. This could potentially provide a direct readout of c-Src PTK kinase 
activity both in vitro and in vivo; at the same time localize the subcellular localization 
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2.2 Introduction 
Protein tyrosine kinases (PTKs) serve as the key components of the signaling 
networks that regulate cell growth and proliferation.
[99]
 Tyrosine phosphorylation is one 
of the key covalent modifications that occur at intercellular communication during 
embryogenesis and adult tissues maintenance of multicellular organisms. The unique 
catalytic mechanism of PTKs is the transfer of the phosphate of ATP to the hydroxyl 
group of a tyrosine in its protein substrate. 
The cells in multicellular organisms communicate via a fundamental mechanism, 
by binding the polypeptide ligands to cell surface receptors that possess tyrosine kinase 
catalytic activity. The transmembrane glycoproteins- receptor tyrosine kinases (RTKs) 
are activated by binding to respective cognate ligands. Signals are transmitted from cell 
surface to cytoplasm via the autophosphorylation of tyrosine residue on the receptor 
themselves, and the phosphorylation on downstream signalling proteins. The activation 
of cellular signalling pathway by RTKs leads to cell differentiation, proliferation, 
migration and even metabolic changes.
[100]
 The RTK family consists of mainly insulin 
receptors and growth factors. For example epidermal growth factor (EGF), fibroblast 
growth factor (FGF), platelet-derived growth factor (PDGF), and nerve growth factor 
(NGF). Apart from RTKs, a large family of nonreceptor tyrosine kinases (NRTKs) exist, 
as the integral components of the signaling cascades triggered by RTKs and by other cell 
surface receptors. Examples of NRTKs are Src, Abl and Janus kinases (Jaks). Many 
PTKs have been identified as oncogens in recent years, underscoring the need for 
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The highly promiscuous and specific catalytic activities of most tyrosine kinases 
can be studied by investigating the localization and activity of the kinase. The v-Src 
oncogen was first identified as transmissible agent responsible for tumor induction in 
chicken. C-Src, the first cellular homologue of the retroviral protein tyrosine kinase (v-
Src) was identified in late 1970s.
 
Widely expressed in normal avian and mammalian 
cells, c-Src PTK can become transforming when expressed at high level. This is usually 
accompanied by replacement or truncation of the carboxyl-terminus and by 
dephosphorylation of a specific tyrosine residue Y527. The well characterized homology 




The catalytic activity of c-Src PTK is governed by two major phosphorylation 
sites, namely the auto-phosphorylation site Y416 and the negative regulatory COOH-
terminal phosphorylation site Y527.
[104]
 C-Src PTK is forced into an “open” 
conformation via the auto-phosphorylation of the key residue Y416 (Figure 2.1.a). 
Phosphorylation at Y416 increases c-Src PTK access to substrates, thereby facilitating 
its maximal activation.
[105]
 Y527 is the primary site of tyrosine phosphorylation in vivo 
by the C-terminal Src Kinase (Csk). Csk is remarkable in its specificity to phosphorylate 
only one class of substrate, a conserved Y527 in the C-terminal tails of the Src 
family.
[106]
 Csk mediated phosphorylation at the inhibitory carboxyl-terminal tyrosine 
residue Y527 promotes the intramolecular interaction between SH2 and pTry527, 
resulting in the “closed” and inactive conformation of c-Src.  Several studies indicated 
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Protein tyrosine phosphatases (PTPs) are important signaling enzymes that serve 
as key regulatory components in various signal transduction pathways. A number of 
protein tyrosine phosphatases are capable of activating Src by dephosphorylating Y527. 
Among them, PTP1B has demonstrated its ability to activate Src PTK in focal adhesions 
and integrin signaling.
 [109]
 and insulin signaling pathway. 
[110]
 Study has showed that 
PTP1B dephosphorylation of the negative regulatory Y527 phosphorylation site is a 
common mechanism of Src PTK activation in a high percentage of human colon cancer 
cell lines.
[111]
 Using purified proteins, Zhang group showed that PTP1B 
dephosphorylates pY416 at a faster rate than pY527. When both SH2 and SH3 domains 
of c-Src were removed, the dephosphorylation rate of pY416 by PTP1B was similar as 
dephosphorylation rate of pY527. The result suggested that pY527 could be protected by 
the intramolecular interaction of both SH2 and SH3 domains.
[112] Fujita’s group also 
showed that PTP1B could potentially dephosphorylate Y416 of active c-Src, as 
suggested by the immunoprecipitation experiment.
[113]
 The catalytically essential 
cysteine (Cys-215) in PTP1B functions as a phosphate-binding cradle, attacking the 
phosphorus atom as a nucleophile. As a result, the substrate trapping mutant (STM) 
(Cysteine-215 to Serine-215) PTP1B will fail to dephosphorylate its substrates. It will 
however retain its ability to recognize and bind to substrates. 
Studies showed that the fluorogenic reagent 4-(aminosulfonyl)-7-fluoro-2, 1, 3-
benzoxadiazole (ABDF) specifically labeled Cysteine 121 residue, leaving other 
cysteines of PTP1B unmodified.
[115] 
ESI mass spectrum indicated that PTP1B is 
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completely modified by one ABDF moiety. ABDF exhibited weak fluorescence until it 
reacts with thiols. Due to the selectivity of ABDF towards Cysteine 121, it is a suitable 
environmental sensitive fluorophore to be used to label PTP1B STM, without perturbing 
the catalytic domain of PTP1B-STM. 
In this study, PTP1B STM was designed and used as a protein biosensor in 
validating c-Src PTK in vivo catalytic activity via binding at phosphoY527 residue. The 
design aimed to label PTP1B STM with environmental sensitive fluorophore-ABDF, 
thereby generating an environmental sensitive protein based biosensor that can be used 
to study the catalytic activity of c-Src in vivo (Figure 2.1b). Upon binding of ABDF 
labeled PTP1B STM with substrate c-Src PTK, changes in fluorescence intensity should 
be observed, due to changes in hydrophobicity of enzyme-substrate local environment. 
The change in signal should be prominent as PTP1B-STM bound tightly to its substrate 
without releasing them, thereby contributing to a constant change in fluorescence 
intensity. 
Firstly, a proof of concept experiment will be done using ABDF labeled PTP1B 
STM against PTP1B substrate peptide which specifically binds to PTP1B active site. 
The microplate experiment will reveal the ability of PTP1B-ABDF in detecting 
fluorescence changes after binding to its substrate peptide at the active site. Next, 
microplate experiments will be done to investigate the protein-protein interaction of 
PTP1B against c-Src PTK. Different recombinant c-Src catalytic domains will be used to 
investigate the direct binding of PTP1B-ABDF against c-Src PTK. Different constructs 
of full length c-Src will also be used to study the function of SH domains in c-Src PTK 
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phosphorylation. Both active and inactive forms of c-Src are essential in revealing the 
binding ability of PTP1B-to c-Src at different phosphorylation stages.  
In vivo experiment will be done to investigate the design and definite potential of 
PTP1B-ABDF as a biosensor, via its potential binding with endogenous c-Src PTK at 
precise sub-cellular compartment. Ultimately, in vivo c-Src substrate stimulation 
experiments will be done to uncover the ability of PTP1B-ABDF in detecting 
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             Active c-Src Kinase                                            Inactive c-Src Kinase 
          - open conformation                                             - close cnformation 
Figure 2.1 (a) c-Src protein tyrosine kinase activation mechanisms. The right panel 
shows a model of the structure of inactivated c-Src PTK that is phosphorylated on the C-
terminal tyrosine Y527 by addition of CSK and ATP. The right panel shows possible 
mechanisms involved in activation of Src PTKs. Y416 represents the auto-
phosphorylation site in the activation loop of Src. Intramolecular interactions of the SH3 





Figure 2.1 (b) The design of PTP1B-ABDF Biosensor. Cys121 of PTP1B substrate 
trapping mutant labelled with Environmental fluorophore ABDF will bind to pY527 
without releasing upon phosphorylation, contributing to a change in PTP1B local 
environment, thereby causing an increase in fluorescence intensity.  
 
 
  51 
2.3 Results and Discussion 
2.3.1 Microplate experiment using ABDF labeled PTP1B-STM and 
PTP1B-DM against PTP1B binding peptide. 
Based on the design of environmental sensitive protein biosensor, PTP1B 
substrate trapping mutant (STM Cys215 Ser215) was used as biosensor to investigate 





ABDF, the environmental sensitive small molecule was shown to label PTP1B at 
Cys121. PTP1B STM was used to create a double mutant (DM), by mutating the residue 
Cys121 to Ala121. PTP1B DM should not be labeled by ABDF; hence, it should not 
show any fluorescence signal before and after binding with the substrate.  
To investigate the possibility of ABDF labeled PTP1B-STM to be used as a 
biosensor, microplate experiment was carried out to observe the binding of PTP1B-STM 
against PTP1B substrate peptide. Fluorescence increase contributed by the change in 
hydrophobicity of the local environment should be observed upon the binding of ABDF 
labeled PTP1B-STM with PTP1B substrate peptide. PTP1B DM was used as a negative 
control as it was not labeled by ABDF due to the lack of Cys121 (mutated to Ala121). 
PTP1B-W/T, PTP1B-STM and PTP1B-DM were labeled with ABDF prior to the 
microplate experiment. Next, the microplate was carried out using ABDF labeled 
PTP1B-W/T, PTP1B-STM and PTP1B-DM against PTP1B substrate peptide.  
Based on the microplate result in Figure 2.2 (b), ABDF labeled PTP1B-DM 
(mutated both active site Cys215 and Cys121) showed almost negligible amount of 
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fluorescence intensity before and after binding to PTP1B substrate peptide. The result 
proved that PTP1B-DM was not labeled by ABDF due to the lack of Cys121. 
PTP1B-STM showed a further increase in fluorescence intensity (roughly 
30RFU-60RFU) upon binding with substrate peptide compared to PTP1B-W/T as shown 
in Figure 2.2 (a), although the fluorescence basal level of PTP1B-W/T was higher after 
ABDF labeling. The failure of PTP1B-W/T in demonstrating further increase in 
fluorescence intensity after binding to the peptide could be caused by the transient 
dephosphorylation of PTP1B-W/T against PTP1B substrate peptide. Unlike PTP1B-
STM which bound to the peptide substrate, PTP1B-W/T left the substrate peptide after 
phosphorylation reaction occurred. All three labeled PTP1B proteins in Figure 2.2 (b) 
did not show any increase in fluorescence signal upon binding with the negative control 
peptide. This experiment showed that ABDF-labeled PTP1B-STM could potentially 
bind to the peptide substrate without releasing, thereby exhibited increase in 
fluorescence intensity. This result bolstered our initial deduction on the use of PTP1B-
ABDF STM potentially as an environmental protein biosensor, to detect the 














Figure 2.2 Microplate experiment of ABDF labeled PTP1B W/T, STM and DM against 
(a) PTP1B substrate peptide and (b) PTP1B negative control binding peptide. 
Fluorescence increase was observed only on the binding of PTP1B STM against PTP1B 
positive control bonding peptide.  
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2.3.2 Microplate investigation on the binding of PTP1B-ABDF against 
c-Src catalytic domains.  
 In order to investigate the direct binding of PTP1B-ABDF with c-Src, three c-Src 
catalytic domain constructs, without SH domains were expressed and purified. 
Investigating the blot using anti-phY416 and anti-phY527 indicated that the expressed 
proteins of all constructs were not phosphorylated at Y416 or Y527. Phosphorylation of 
Y416 was observed on both Y527M catalytic domain and W/T catalytic domain upon 
ATP addition (Figure 2.3 II Lane 1 and Lane 4). Phosphorylation of Y527 was observed 
on 416M catalytic domain upon ATP addition, but not on W/T catalytic domain (Figure 
2.3 III Lane 3). With the addition of ATP, W/T catalytic domain which contains both 
Y416 and Y527 may compete for autophosphorylation. Y416 which is located at 
tyrosine kinase catalytic domain is the major auto-phosphorylation site of c-Src. 
However, other investigators have reported the auto-phosphorylation of Y527.
[120]
 The 
autophosphorylation of Y527 is showed to be more prominent with the  disruption of 
kinase catalytic domain where Y416 is positioned.
[121]
  
 Microplate experiment was carried out to investigate the binding of PTP1B-
ABDF with three c-Src catalytic domains respectively (Figure 2.4, 2.5 and 2.6). A 
concentration gradient of 0uM to 30uM of Src catalytic domains were incubated with 
10uM of PTP1B-ABDF for 30 minutes on 384-well plate. Two sets of gradient 
experiment, one with ATP incubation and one without ATP incubation were carried out 
simultaneously. After 30 minutes, the plates were scanned at 520nm. A gradual increase 
and decrease in fluorescence intensity was observed on both phosphorylated and non-
phosphorylated c-Src catalytic domains of respective constructs. 
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 The initial stage of this study was carried out using PTP1B-ABDF against 
PTP1B substrate binding peptide. The result supported the hypothesis that STM P1B-
ABDF could potentially be used as a protein biosensor to monitor in vivo c-Src catalytic 
activity. However, the haphazard trend of the microplate result using c-Src catalytic 
domains failed to demonstrate the increase in Y416 and Y527 phosphorylation, although 
both sites are phosphorylated upon addition of ATP. The microplate reading of three c-
Src catalytic domain constructs indicates that the lack of SH domains could have 
possibility contributed to the lost of signal observed. Study showed that the binding of 
SH3 domain of c-Src kinase to the C-terminal proline-rich region and the N-terminal 
tyrosine residues of PTP1B is required for the activation of c-Src kinase.
[122]
 In addition; 
pY527 may not have access to an adjacent SH2 hydrophobic pocket as indicated by c-
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 The three c-Src catalytic domains used is as following:  
1.    ---YOPH----Tyr416----Tyr527----6XHis     c-Src W/T catalytic domain 
2.  ---YOPH----Tyr416------X527----6XHis      c-Src 527 mutant catalytic domain 
3.  ---YOPH------X416----Tyr527----6XHis      c-Src 416 mutant catalytic domain 
 
 









        IV. 
 
Figure 2.3 I. Coomassie blue gel indicated the three expressed catalytic c-Src domains. 
The western blot of three c-Src catalytic domain constructs against II. Anti-phY416. III. 
Anti- phY527. Table IV indicates the state of phosphorylation of each catalytic c-Src 
constructs upon ATP incubation.   
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Figure 2.4 Microplate result with increasing concentrations of 416M c-Src catalytic 





Figure 2.5 Microplate result with increasing concentrations of 527M c-Src catalytic  
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2.3.3 Microplate investigation on the binding of PTP1B-ABDF against 
pRSET c-Src, a catalytically impaired full length c-Src.  
The in vivo interaction of PTP1B-ABDF with a catalytically impaired full length 
c-Src kinase containing SH domains was further investigated using microplate. This 
kinase defective Src mutant pRSET c-Src kinase has a single point mutation Lysine 295 
to Methionine 295, which allows it to be expressed strongly in bacteria.
[123]
 The active 
full length c-Src showed that Y416 position was not phosphorylated despite addition of 
ATP (Figure 2.7 II Lane2). The Y527 was however phosphorylated before and after 
addition of ATP (Figure 2.7 III Lane1 and Lane2). Y527 was further phosphorylated 
upon addition of ATP and CSK (Figure 2.7 III Lane3). Three sets of gradient 
experiment, one without ATP incubation, one with ATP incubation and one with ATP 
and CSK incubation were carried out simultaneously. After 30 minutes, the plates were 
scanned.  
Y416 was not phosphorylated when expressed in recombinant pRSET c-Src. The 
increase in fluorescence signal was negligible without addition of ATP. As indicated by 
the western blot result, Y416 did not undergo auto-phosphorylation with the presence of 
ATP. This could be due to face that PRSET c-Src was catalytically impaired and it 
would remain inactive all the time. The increase in fluorescence intensity observed was 
also negligible, similar to that of the reaction without ATP. Y527 seemed to be present 
in phosphorylation form in recombinant PRSET c-Src with and without addition of ATP 
to the reaction. The addition of CSK together with ATP gave rise to an increase in Y527 
phosphorylation as indicated by western blot. A slight increase in fluorescence intensity 
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was observed on PRSET c-Src incubated with ATP and CSK. As indicated in Figure 2.8. 
The increase observed could be contributed by phosphoY527 binding to PTP1B-ABDF. 
 
          I. Anti c-Src                     II. Anti phTyr416                 III. Anti phTyr527 
 
              















Figure 2.7 The western blot of three PRSET c-Src (catalytically impaired full length c-
Src) reactions against I Anti c-Src II Anti-phY416 and III Anti-phY527. Table IV 
indicates the state of phosphorylation of PRSET c-Src construct upon ATP and CSK 
incubation.   
 





Figure 2.8 Microplate reading of PRSET c-Src incubated with PTP1B-ABDF.  An 
increase in fluorescence intensity was observed on PRSET c-Src when ATP and CSK 
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2.3.4 Microplate investigation on the binding of PTP1B-ABDF against 
full length active recombinant c-Src and CSK stimulation. 
The in vivo interaction of PTP1B-ABDF with full length active c-Src PTK 
containing SH domains was further investigated using microplate. Upon addition of 
ATP, the full length c-Src is phosphorylated at Y416 (Figure 2.9 I Lane2) and slighly 
phosphorylated at Y527(Figure 2.9 II Lane2). Upon addition of ATP with CSK, the 
phosphorylation of Y527 (Figure 2.9 II Lane4) increase significantlyand Y416 remained 
phosphorylated (Figure 2.9 I Lane 4) .  
Full length active c-Src PTK was incubated with ATP to promote auto-
phosphorylation. After that, microplate experiment was carried out to investigate the 
binding interaction between c-Src PTK with ABDF-labeled PTP1B STM. An increase in 
fluorescence signal was observed upon binding of PTP1B-ABDF with c-Src PTK as 
indicated in Figure 2.10. This increase in signal should be contributed to the binding at 
phY416 caused by autophosphorylation. A further increase was observed as ATP and 
CSK was added into the reaction. With the addtion of ATP and CSK, both Y416 and 
Y527 would be phosphorylated. This significant increase could be contributed by the 
phosphorylation at both Y527 and Y416. PTP1B-ABDF  did not showed any binding 
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     I. Anti phY416                                                II. Anti phY527 
             





        
            
            
            
    III.  
 
 
Figure 2.9 The western blot of full length active recombinant c-Src. I. anti-ph Tyr416 
II.Anti-phTyr527. Table III indicates the state of phosphorylation of active full length c-
Src constructs upon ATP and CSK incubation.   
 
 
  64 
 
 
Figure 2.10 Microplate reading of full length active recombinant c-Src with ATP 
addition. An increase in fluorescence intensity was observed upon PTP1B-ABDF 
binding with recombinant c-Src. A further increase in fluorescence intensity was 
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2.3.5 In vivo imaging using PTP1B-ABDF against endogenous c-Src 
Protein Tyrosine Kinase. 
 In vivo imaging experiment was carried out in MCF 7 cells, in order to 
investigate the possibility of in vivo interaction of PTP1B-ABDF substrate trapping 
mutant (Cysteine121 Serine121) with endogenous c-Src PTK.  
C-Src PTK was deduced to bind to both pY416 and pY527 of c-Src PTK. The 
cells were incubated with ABDF-labeled PTP1B for 1 hour. The fluorescent microscope 
imaging result indicated that PTP1B-ABDF exhibited plasma membrane localization in 
MCF7 cells as shown in Figure 2.11. Immuno-fluorescence, IF was carried out using 
anti-c-Src to further confirm the exact subcellular localization of endogenous c-Src. The 
fluorescence imaging result of Figure 2.11 showed that PTP1B-ABDF overlaid 
completely with Anti-c-Src antibody. This result confirmed the ability of PTP1B-ABDF 
to potentially serve as a protein biosensor of c-Src PTK, with the ability to locate 
endogenous c-Src tyrosine kinase. To further investigate the accuracy of PTP1B-ABDF 
binding with endogenous c-Src at phY416 and phY527, both anti-phY416 and anti-
phY527 is used for IF experiment. The result from Figure 2.12 showed that PTP1B-
ABDF overlaid completely with both anti-phY416 and anti-phY527 c-Src antibody, 
indicating PTP1B-ABDF in vivo binding with endogenous c-Src at both phY416 and 
phY527 positions. The result showed that STM P1B-ABDF could potentially be used as 
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              DIC                       PTP1B-ABDF              Anti c-Src                  Overlay 
 
Figure 2.11 Immuno-fluorescence using anti-c-Src on MCF-7 Cell. The PTP1B-ABDF 
exhibited plasma membrane localization in MCF7 cells. IF experiment showed that the 
anti-c-Src overlaid completely with PTP1B-ABDF. Bar, 10um. 
        
 
          PTP1B-ABDF                       Anti- phY416                      Overlay 
 
                                                  
           PTP1B-ABDF                       Anti- phY527                        Overlay 
 
Figure 2.12 IF experiment showed that both anti phY416 and anti phY527 overlaid 
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2.3.6 The use of PTP1B-ABDF to monitor pY416 phosphorylation in 
MCF7 cells induced by PDGF stimulation. 
In vivo imaging experiment was carried out in PDGF stimulated MCF7 cells, in 
order to investigate the possibility of in vivo interaction of PTP1B-ABDF substrate 
trapping mutant (Cysteine121 Serine121) with activated endogenous c-Src PTK.  
C-Src PTK binds to the PDGFR via its SH2 domain interacting with 
phosphotyrosine residues in the juxta-membrane region of the PDGFR. Study showed 
that treatment of fibroblasts with PDGF causes an increase in c-Src PTK catalytic 
activity. In addition, c-Src PTK binding directly to PDGFR induces both serine and 
tyrosine phosphorylation of Src.
[117] 
PDGF-induced phosphorylation at two serine 
residues at the N-terminal and Y416 in the catalytic domain of Src play an important 
role in the activation of Src PTKs.
[118] 
MCF7 cells were incubated with various 
concentrations of PDGF from 0ng/mL to 100ng.mL for 30 minutes. Increase in 
fluorescence intensity was observed as PDGF concentration increased from 0ng/mL to 
100ng/mL. The increase in fluorescence intensity of individual PDGP concentration is 
compared by percentage (Figure 2.13), based on relative fluorescence intensity unit of 
the microscope read out. The fluorescence of ABDF was observed to increase linearly 
with the increase of PDGF concentrations. This increase in fluorescence signal could be 
contributed by Y416 phosphorylation induced by PDGF. The result further supports the 
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Figure 2.13 PTP1B-ABDF was used to monitor pY416 phosphorylation in MCF7 cells 
induced by PDGF stimulation. Increase in fluorescence signals were observed as PDGF 
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2.3.7 In vivo imaging using PTP1B-ABDF against c-Src kinase 
transfected cells against H2O2 stimulation. 
 In vivo imaging experiment was carried out in c-Src kinase transfected HEK293T 
cells which are further stimulated with H2O2, in order to investigate the possibility of in 
vivo interaction of PTP1B-ABDF substrate trapping mutant (Cysteine121 Serine121) 
with pY416 activated endogenous c-Src PTK.  
 The binding of C-Src PTK to H2O2 had been reported to induce c-Src kinase 
activation via phosphorylation of Y416 residue.
[119]
 We further investigated the ability of 
PTP1B-ABDF to monitor the in vivo activation of c-Src kinase by stimulating the c-Src 
kinase transfected CHOK cells with 5mM of H2O2. The CHOK cells were transfected 
with W/T c-Src kinase prior to H2O2 stimulation. This was done to potentially achieve a 
more apparent increase of Tyr416 phosphorylation. IF experiment using anti-phY416 
showed an obvious increase in Y416 phosphorylation for H2O2 stimulated transfected 
CHOK cells upon fixation. The cells were later incubated with PTP1B-ABDF. The 
result of Figure 2.14 showed that PTP1B-ABDF demonstrated increase in fluorescence 
intensity at plasma membrane; from non-transfected CHOK cells to H2O2 stimulated 
transfected CHOK cells. PTP1B-ABDF overlaid majorly with anti-phY416 antibody 
along the plasma membrane of CHOK cells.  
 The increase in Y416 phosphorylation upon H2O2 stimulation was confirmed 
using western blot against non-transfected, transfected and H2O2 stimulated CHOK cell 
lysate. Investigating the blot using anti-c-Src (Figure 2.7. I) indicated that the amount of 
c-Src kinase increases upon W/T c-Src transfection (Figure 2.15.I Lane 2). No further 
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increase in the total amount of c-Src kinase was observed in transfected CHOK lysate 
upon H2O2 stimulation (Figure 2.15.I Lane3). Investigating the blot using anti-ph-Y416 
indicated that Y416 phosphorylation increased upon W/T c-Src transfection (Figure 
2.15.II Lane2). A further increase in Y416 phosphorylation (Figure 2.15.II Lane3) was 
observed in transfected CHOK lysate upon H2O2 stimulation. 
This increase in fluorescence signal might be contributed by Y416 
phosphorylation stimulated by H2O2. Supported by western blot using anti pY416, the 
biosensor could only locate endogenous active c-Src majorly along plasma membrane.   
However, PTP1B-ABDF failed to locate the precise location of endogenous active c-Src 
kinase. The result supports the possible use of STM PTP1B-ABDF as an in vivo protein 
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Figure 2.14 H2O2 stimulation experiment. The w/t c-Src transfected CHOK cells 
demonstrated a six fold fluorescence increase compared to non-transfected CHOK cells. 
The transfected CHOK cells demonstrated a further three fold increase in fluorescent 
intensity after stimulated with 5mM of H2O2. The increase in Y416 phosphorylation on 
both transfected cells and H2O2 stimulated transfected cells were also demonstrated by 
anti-phY416 antibody. IF experiment showed that anti-phY416 antibody overlaid 
majorly with PTP1B-ABDF along the plasma membrane of CHOK cells (indicated by 
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   I. Anti c-Src                                                         
    
                             L1                     L2                L3                                          
                  Nontransfected     Transfected    Transfected                          
                         CHOK              CHOK         CHOK+H2O2                              
 
Figure 2.15.I. H2O2 stimulation experiment on c-Src transfected CHOK cells, confirmed 
by Western Blot using anti-c-Src. The CHOK cell lysate demonstrated an increase in c-
Src upon W/T c-Src kinase transfection as indicated in Lane 2, and upon stimulation 
with 5mM of H2O2 as indicated in Lane 3.  
 
 
II. Anti phY416   
                               L1                  L2                  L3                                          
                  Nontransfected     Transfected    Transfected                          
                         CHOK              CHOK         CHOK+H2O2                              
 
Figure 2.15.II. H2O2 stimulation experiment on c-Src transfected CHOK cells, 
confirmed by Western Blot using anti-phY416. The CHOK cell lysate demonstrated an 
increase in Tyr416 phosphorylation upon W/T c-Src kinase transfection as indicated in 
Lane 2. The transfected CHOK cells demonstrated a further increase in Y416 
phosphorylation upon stimulation with 5mM of H2O2 as indicated in Lane 3.  
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2.4 Conclusion 
The use of ABDF labeled PTP1B substrate trapping mutant (STM) as an 
environmental sensitive biosensor to detect the catalytic activity of c-Src protein tyrosine 
kinase (PTK) was showed to be encouraging. The use of PTP1B substrate peptide 
proved that ABDF labeled PTP1B STM was able to detect change in local environment 
when bound against its substrate peptide, unlike PTP1B W/T which bound to its 
substrate transiently. The binding of PTP1B-ABDF with c-Src PTK catalytic domains 
demonstrated that the correct orientation for phY527 was useful in the detection of c-Src 
catalytic activity. The result suggest that the lack of SH domains made it impossible for 
PTP1B-ABDF which bound to phY527 to exert change in fluorescence intensity, 
because c-Src catalytic domain remained as open conformation or linear when phY527 
was unable to coil back to the SH2 domain pocket. The use of catalytically impaired full 
length PRSET c-Src showed that PTP1B-ABDF bound to c-Src PTK upon Y527 
phosphorylation by both ATP and CSK. PTP1B-ABDF could possibly be used to 
demonstrate the catalytic activity of c-Src PTK by change in fluorescence intensity when 
bound to autophosphorylated active full length c-Src at phY416, and CSK-ATP induced 
phosphorylation at phY527.  
In vivo experiment together with plasma membrane co-localization experiment 
showed that PTP1B-ABDF could detect endogenous c-Src PTK at sub-cellular 
compartment (plasma membrane) supported by c-Src antibody. Both PDGF stimulation 
and H2O2 stimulation experiments showed that the slight increase in PTP1B-ABDF 
fluorescence detection was directly comparative to the increase in phosphorylation level 
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at Y416. However, the change in signal observed was not prominent visually. Upon 
H2O2 stimulation, the co-localization of PTP1B-ABDF with anti-phY416 could be 
observed only along the plasma membrane of CHOK cells. The biosensor failed to 
depict the precise localization of both endogenous active and inactive c-Src PTK.  
Microplate experiment could have been done by using a full length active c-Src 
in order to obtain a better comparison for PTP1B-ABDF binding against active and 
inactive c-Src kinase. The challenge remains in expressing recombinant full length c-Src 
with complete activity. Bacilo virus or mammalian expression system could potentially 
be used as an alternative approach from bacterial expression system. In addition; 
determining the net c-Src kinase activity could be complicated using PTP1B which 
catalyzes the dephosphorylation of both the inhibition site (Y527) and activation site 








  75 
Chapter 3 




Biological circuits function at single cellular level. Imaging serves as the most 
appropriate tool to investigate and quantify data at single-cell resolution, and do so 
noninvasively, offering insights that cannot be discovered by in vitro approaches. With 
standardized reporters and imaging conditions, high-throughput imaging allows 
intravital imaging to capture data approaching the same large scale as today’s -Omic 
approaches with improved temporal and spatial resolution.  
In this chapter, we describe the use of high- throughput imaging to systematically 
identify novel subcellular localization of protein-tyrosine phosphatases (PTPs). We 
demonstrate the use of gateway cloning to rapidly generate C- and N-terminal GFP 
fusion protein to possibly examine the intracellular localization of more than 120 
transiently expressed fusion PTPs. This is crucial as protein localization in most cases is 
closely related to its function.  
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3.2 Introduction 
3.2.1 The Role of PTPs in Protein Phosphorylation 
Protein phosphorylation is one of the most ubiquitous posttranslational 
modifications in protein activity regulation, responsible for a variety of cellular 
regulatory processes. The removal or addition of a phosphoryl moiety from a protein is 
capable of generating a recognition motif for protein-protein interactions, controlling 
protein stability, at the same time modulating enzyme activity. Protein tyrosine 
phosphatases (PTPs) serve as essential signaling enzymes which are responsible for a 
diverse array of cellular network as 30% of cellular proteins are phosphoproteins.
[124]
 
Recent biochemical research indicates that PTPs represent a novel platform for drug 
discovery. Tyrosine phosphorylation has shown to increase by 1%–2% of the total 
protein phosphorylation in the cell, upon oncogenic transformation or growth factor 
stimulation. It is apparent that tyrosine phosphorylation is essential in controlling normal 
cellular growth, ranging from differentiation, metabolism, cell cycle, cell-cell 
communications, gene transcription, ion channels, and the immune response, to cell 
survival.
[125]
 Malfunction of PTP activity is associated with many human diseases 
including cancers, hypertension, diabetes and rheumatoid arthritis. 
Tyrosine phosphorylation is reversible and dynamic, governed by the opposing 
activities of protein tyrosine phosphatases (PTPs) protein and tyrosine kinases (PTKs). 
PTPs are capable of exerting both positive and negative effects on cellular network as 
the deregulation of PTP activity can lead to the pathogenesis in many human diseases. 
One of the classic studies using PTP1B knockout mice showed that the loss of PTP1B 
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activity result in enhanced insulin sensitivity and resistance to weight gain in mice, 
indicating PTP1B as a major negative regulator of insulin signaling in both muscle and 
liver.
[126-127]
 A part from diabetes, PTPs also play a vital role in inhibitory and 
stimulatory effects on cancer-associated signaling processes, making PTPs novel drug 
targets for the development of medicinal agents. The prerequisite for the successful 
development of potent and selective PTP inhibitors would require detailed 
understanding of the molecular basis of PTP substrate specificity. An exclusive 
understanding of PTPs function could help us in the development of novel anticancer 
drugs. 
Understanding of complex PTPs biological circuits will require the viewing of 
such dynamic system at protein level and localizations in situ. In situations where 
limited a priori information is known, investigators have the choice to fall back on high-
throughput imaging techniques where the use of automated instrumentation and 
advanced analysis tools, has become practical for high-throughput discovery of new 
biology. Being able to capture quantitative data with single cell resolution from intact 
life cells with minimum perturbation, imaging has the inimitable capability to approach 
system biology circuit as information science. High-throughput imaging provides 
insights to large scale biological interacting network, with spatial and temporal 
resolution. Mammalian cells are highly compartmentalized. In most cases, the 
subcellular localization of protein is closely related to its functions. With existence of 
automated instrumentation and analysis tools, our aim is to probe the subcellular 
localization PTPs with its’ ORF sequences in a rapid, convenient and large scale 
approach.  
















Figure 3.1 Overall screening strategy: LR reaction was performed with protein 
phosphatase entry clone and pDEST destination vector. The pDEST expression clones 
were subsequently transfected into mammalian cells for subcellular localization analysis. 
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3.3 Results and Discussion 
3.3.1 LR reaction and HT imaging of Human ORFeome protein 
phosphatase plasmids 
The aim of this study is to probe the subcellular localization of protein 
phosphatase with its’ ORF sequences in a rapid, convenient and large scale approach, 
using reverse proteome approach. The human ORFeome v1.1, resource containing 
roughly 12000 Gateway entry clones (generated using Mammalian gene collection) from 
Open Biosystem, allowed easy insertion of thousands of open reading frames (ORF) into 
choice of expression system, from prokaryotic, mammalian to viral. The large scale 
functional analysis of ORF and encoded proteins required the use of rapid, high capacity 
and efficient cloning system. Gateway cloning system was applied because it omits the 
conventional cloning method which uses restriction enzymes and ligase. Gateway 
cloning amplified the ORF with high efficiency by recombination and maintained the 
reading frame and orientation. It also eliminates the need of re-sequencing as the 
consistent results throughout the experiment using the same clone from target 
identification to validation were ensured.  
We started from preparing the 119 entry clones protein phosphatase plasmids for 
ligation use. The 12000 clones were provided in 2-ml tubes from Open Biosystem. Each 
tube contained LB medium supplemented with 8% glycerol and the appropriate 
antibiotic.119 protein phosphatase were picked from the 12000 clones and inoculated 
into LB with appropriate antibiotic and the clones were grown for 12hr/overnight at 
37C. Plasmids were run on DNA gel to check for success rate and purity level before LR 
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reaction was carried out. As shown by the DNA gel (Figure 3.2), the purity of plasmids 
using high throughput manner is sufficient to be used for LR reactions. The high 
throughput Miniprep success rate is approximately 95%, a relatively reasonable success 
rate for HT instrumentation. The plasmids were kept at -20C, to be ready for LR 
reaction. 
To ligate 119 Human ORFeome phosphatase entry clones into Gateway 
Destination Vector, 119LR reactions were performed using 96-well plate. Both the 
Gateway Destination Vectors pDEST47 and pDEST53 contained GFP tag at C- terminal 
and N-terminal respectively, and a cytomegalovirus (CMV) promoter which allowed 
expression in mammalian cell line. To insert genes into gateway destination vectors, 
primers were designed that flank the gene of interest, and also carry the necessary 
recombination sites (AttB) required for the recombination reaction. To perform the LR 
reaction, 300ng of pCDNA-Dest47/53 was added into 5 X LR Buffer, 1 X TE Buffer 
and 4.0uL of Miniprep entry clone plasmid.  The reaction was set on 96-well PCR plate 
or tubes. The plate or tubes were incubated at 25°C overnight. The LR mixes were 
transformed into Top 10 competence cells. The transformed cells were grown on 6-well 
LB plates. The diameter of the plate used was shown to be optimum for number of 
grown colony bounded by growing space. Next, colony PCR was performed to screen 
for the correct PTP clone. Clones were verified based on the ORF size. As shown in 
Figure 3.3, amplified fragment size matched with the ORF of 119 human protein 
phosphatase. The LR reaction successful rate is approximately 90% based on the result 
indicated by the DNA gel. 
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Figure 3.2 Plasmids of Human ORFeome protein phosphatase entry clone, run on DNA 
gel after Miniprep. Entry clones plasmids were grown on LB/ Strep overnight at 37C. 
Miniprep was done next day using liquid handler on 96-well plate samples. Plasmids 
were run on DNA gel to check for success rate and purity level before LR reaction was 
carried out. As shown by the DNA gel of Figure 3.2, the purity of plasmids using high 
throughput manner is fair enough to be used for LR reactions. The high throughput 
Miniprep success rate is about 95%. (For protein phosphatase plasmids A1-D2, view 
appendix for plasmids ID and description). 
 
 
                                        Ladder 
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Figure 3.3 Plasmids from colony PCR which was performed to screen for the correct protein phosphatase clones based on the 
ORF size. Both pDEST47 and pDEST53 contained GFP tag at C- terminal and N-terminal of each clones were screened 
simultaneously. The LR reaction successful rate is approximately 90% based on the result indicated by the DNA gel.  
(For protein phosphatase plasmids A1-F12, view appendix for plasmids ID and description
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3.3.2 Subcellular localization of Human ORFeome protein phosphatase 
in pDEST47 & pDEST53 expression host. 
In order to monitor the in vivo subcellular localization of protein phosphatases 
expressed from vector generated from previous section, we carried out the transient 
transfection into HEK293T mammalian cell line followed by HT fluorescence imaging 
using semi-automated microscope. 10 protein phosphatase entry clone plasmids with 
correct ORF size were transiently transfected into HEK 293T mammalian cell line, 
seeded in 96-well plate. After 18 to 24 hours, GFP-PTP fusion proteins were mature for 
visualization under fluorescence microscope at magnification of 60X. The optimized 
maturation time used in this study was 18 hours.  
Different GFP fusion-phosphatase entry clone expressed are known to localize to 
a wide variety of intracellular compartments. For instance, Protein phosphatase 1 is 
known to be localized in cytoplasm, Protein phosphatase 2C Eta in the nucleus and 
Protein tyrosine phosphatase in the endoplasmic reticulum. In some cases, GFP is 
known to have aberrant effect on the cellular localization of the fusion protein. In order 
to recognize such aberrant effect GFP might have on the localization of the fused protein 
phosphatase, we carried out the imaging experiment to compare the subcellular 
localization of protein phosphatase fused with GFP at C- and N- terminal in PDEST 
destination vectors respectively. Based on the current imaging data gathered, 8 out of 10 
transfected clones exhibited same subcellular localization for both C- and N- terminal 
fusion GFP; the remaining 2 samples either demonstrated different subcellular 
localization or failed to exhibit GFP signals under GFP channel during screening. 
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 Figure 3.4 showed an example of cytoplasm localization of a particular protein 
phosphatase clone for both C- and N- terminal fusion GFP, pDEST47 and pDEST53.  
 
Localization of pDEST47 
GFP                               
 
Localization of pDEST5 
GFP                               
 
Figure 3.4 Examples of GFP-PTP entry clone in vivo localization in HEK293T cells 
after transfection, exhibiting cytoplasm localization for both c- and N-terminal pcDNA-
pDEST47 and pcDNA-pDEST53 vectors. 80% of the entry clones exhibit same 
subcellular localization with both N- and C-terminal GFP fusion respectively. Bar, 
10um. 
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Both C- and N-terminal pcDNA-pDEST47 and pcDNA-pDEST53 vectors were 
transfected into HEK293T to view the PTPs subcellular localization using 96-well plate, 
in a high throughput manner using automated microscope. Nucleus stain, Hoechst 33342 
dye was used to distinguish the subcellular compartment, so that a clear view of the 
localization can be achieved. Cells were stained with 1 g/mL Hoechst for 10 min at 
room temperature, washed with 1XPBS before mounting. 6 of the clones exhibited the 
accurate subcellular localization as reported, indicating GFP fusion did not affect the 
subcellular localization of protein phosphatase in these cases. Examples of protein 
phosphatase with correct subcellular localization for both C- and N-terminal GFP fusion, 
were shown in Figure3.5. The failure for protein phosphatase to exhibit correct 
localization could be due to a few factors. Firstly, the localization signal of the protein 
phosphatase could be affected by the C- or N-terminal fusion GFP. Secondly, the 
transiently transfected entry clone could be lacking in some specific post translational 
modification contributing to the failure to localized into the correct cellular 
compartment. Thirdly, it is known that protein interacting partner will affect the 
localization of a particular protein.   
The overall work flow for this HT protein phosphatase imaging was considered 
rapid, efficient and throughput amenable, from automated Miniprep to transfection and 
image capturing. We were hoping to unravel novel PTP localization with such method, 
at the same time adding exciting information into the existing known database, as a 
number of PTPs localizations and functions remained ambiguous. Subcellular trackers 
e.g. mito-tracker or lyso-tracker can be used to further pinpoint the exact localization by 
exhibiting co-localization with the transiently expressed GFP-PTPs. 




Figure 3.5 Subcellular localization of three protein phosphatases viewed under GFP-
channel, using fluorescence microscope at 60X magnification were summarized in table 
above. 80% of the entry clones showed the same subcellular localization as reported. It 
is possible to discover novel unreported subcellular localization of protein phosphatase 








































  87 
3.4 Conclusion 
We have identified subcellular localization of part of the protein phosphatase 
encoded by Human ORFeome protein phosphatase entry clones. The use of high 
capacity Gateway cloning technology make it possible to rapidly transfer coding 
sequence, between functional vectors and generate the desired expression clones. Our 
preliminary result generated from the well organized work flow indicated that novel 
interesting subcellular localization of PTPs can be determined. This could serve as a 
jumpstart for further analysis on interesting protein phosphatase or any class of protein 
candidate from Human ORFeome. Exciting data could be further generated using this 
platform in future work, for example the investigation translocation of protein 
phosphatase upon drug stimulation. This approach is highly amenable for automated 
high-throughput capacity, allowing the simultaneous and real time visualization of 
protein phosphatase subcellular localization to be discovered. Cutting edge development 
in biological techniques and advance technology in instrumentation, promise to drive the 
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Chapter 4. 
Experimental Procedures 
4.1 General  
All chemicals used in this dissertation were purchased from commercial vendors 
and used without further purification unless otherwise stated. All in-gel fluorescence 
scans were performed using Typhoon™ 9200 fluorescence gel scanner (Amersham) and 
images were analyzed/quantitated with the ImageQuant™ software (Amersham). 
 
4.2 Chapter 2 
4.2.1 General 
4-Fluoro-7-sulfamoylbenzofurazan-ABDF (F3639) was purchased from Sigma-
Aldrich. Antibody: Anti-pY416 (#2101) and anti-pY527 (#2105) were purchased from 
Cell Signaling Technology. Anti-c-Src tyrosine kinase (sc8056) was purchased from 
Santa Cruz. Hoechst dye (33342) was purchased from Molecular probes. PTP1B 
substrate trapping mutant (Ampicillin-resistance) and the catalytic impaired full length 
c-Src kinase (chicken c-Src residues 83-533, Kanamycin-resistance) in Top10 
propagating host were provided lab member Tan Lay Pheng. Four c-Src kinase catalytic 
domain (Kanamycin-resistance) constructs were provided by lab member Liu Kai in 
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Top10 propagating host. Both full length and catalytic domains of c-Src kinase were 
expressed and purified in house. Proteins were further purified using FPLC size 
exclusion column (GE Lifescience). All c-Src kinase constructs in E. coli strain BL21-
DE3 expression host were co-expressed with YOPH pCDFDuet-1 vector (Streptomycin-
resistance) to help in higher soluble protein yield. Wide type full length c-Src construct 
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4.2.2 Site directed mutagenesis of PTP1B STM, mutating Cys121 to 
Ser121  
Site directed mutagenesis of genes was carried out to convert PTP1B substrate 
trapping mutant (STM) into double mutant by mutating Cys 121 to Ser121. The one to 
two base pair substitution mutation was designed into a forward primer that flanks the 
mutation by 20-25 base pairs on either side of the mismatch. The reverse primer was the 
exact complement of the forward primer. The mutation was introduced into the template 
using the primers during the PCR reaction, following which the parental strand without 
the mutation was digested away using the enzyme DpnI which cleaves away the 
methylated strand of the parental DNA. The plasmid template PCR was carried out 
using the Pwo polymerase (Roche), the PCR reaction mix contained the following. 5 U 
of the Pwo polymerase, 600 pM of each primer , 0.2 mM each dNTP, 50-100 ng of 
template, in a 50 μL reaction, using the following program, 94 °C, 2 min; 10 cycles of 
94 °C 15 sec; 55 °C, 30 sec; 6 min, 72 °C and 15 cycles of 94 °C, 15 sec; 55 °C, 30 sec; 
6 min /Cycle (cycle extension) 72 °C, with a final 10 min, 72 °C extension. The parental 
template was digested using DpnI (NEB) and transformed into XL1blue cells following 
PCR. The transformants were DNA sequence verified. 
PTP1B STM: 5’ GAAAGG TTCGTTAAAA TGCGCACAAT ACTGGCCAC 3' 
1. FR Primer: 5’ GAAAGG TTCGTTAAAA TCCGCACAAT ACTGGCCAC 3’ 
2. RV Primer: 5’ GTGGCCAGT ATTGTGCGGA TTTTAACGAA CCTTTC 3’ 
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4.2.3 Expression and Purification of c-Src constructs.  
Recombinant c-Src (residues 83-533) and three c-Src catalytic domain tagged 
with hexahistidine tag at their N-terminal, were expressed in the E. coli strain, BL21 
(DE3). Briefly, all C-Src plasmids, one catalytically impaired full length c-Src and three 
c-Src catalytic domains were co-transformed with YOPH pCDFDuet-1 plasmids into E. 
coli BL21(DE3) cells and plated on LB agar with kanamycin (50 μg/mL)/streptomycin 
(50 μg/mL) and grown overnight at 37 °C. The next day, the colonies from the plates 
were resuspended in Luria Bertani (LB) medium supplemented with 50 μg/mLof 
kanamycin and 50 μg/mL streptomycin. Cultures were grown to an OD600nm of 1.2 at 
37 °C, cooled for 1 h with shaking at 18 °C prior to induction for 16 h at 18 °C with 0.2 
mM IPTG.  
 
4.2.4 Expression and Purification of CSK constructs.  
Recombinant GST tag at N-terminal, were expressed in the E. coli strain, BL21 
(DE3). Briefly, CSK was co-transformed into E. coli BL21 (DE3) cells and plated on LB 
agar with kanamycin (50 μg/mL and grown overnight at 37 °C. The next day, the 
colonies from the plates were resuspended in Luria Bertani (LB) medium supplemented 
with100 μg/mL of kanamycin. Culture was grown to an OD600nm of 1.2 at 37 °C, 
cooled for 1 h with shaking at 18 °C prior to induction for 16 h at 18 °C with 0.2 mM 
IPTG.  
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4.2.5 Expression and Purification of PTP1B constructs.  
Recombinant PTP1B substrate trapping mutant (Cysteine  Serine) and PTP1B 
double mutant tagged with hexahistidine tag at their N-terminal, were expressed in the 
E. coli strain, BL21 (DE3). Briefly, both PTP1B all plasmids were transformed E. coli 
BL21 (DE3) cells and plated on LB agar with kanamycin (50 μg/mL)/ and grown 
overnight at 37 °C. The next day, the colonies from the plates were resuspended in Luria 
Bertani (LB) medium supplemented with 50 μg/mLof kanamycin. Cultures were grown 
to an OD600nm of 1.6 at 37 °C, cooled for 1 h with shaking at 18 °C prior to induction 
for 16 h at 18 °C with 0.4 mM IPTG.  
 
(a)                                                                   (b)                        








Figure 4.1 (a) CSK purified proteins showed above was cleaved with factor Xa (from 
NEB) to remove off the GST tag. (b) Three constructs of purified PTP1B proteins.  
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4.2.6 Protein Purification Procedues. 
4.2.6.1 Ni-NTA column  
 The 6X-HIS tagged proteins were purified using Ni-NTA resin (QIAGEN). The 
frozen pellets were thawed on ice, lysis buffer (50 mM Tris, 500 mM NaCl, 5% 
glycerol, 25 mM imidazole, pH 8.0) was added followed by addition of Lysozyme 
(Sigma) at 1 mg/mL and incubation was continued on ice for 30 min. The volume of 
lysis buffer added was 100X concentration, e.g., 50 mL starting culture volume was 
concentrated to 0.5 mL lysis buffer. The cells were sonicated for further lysis. 
Sonication was carried out with 30% amplitude, 10 sec ON, 10 sec OFF, using the 
SONICS
™ 
(Newtown, CT, USA) VIBRA CELL. The lysed cells were then centrifuged 
at 13,000 rpm for 30 min at 4 °C. The supernatant was incubated with 100 μL Ni-NTA
™ 
beads / 100 mL culture, for 2 hr or overnight at 4 °C. The 6XHIS tagged proteins were 
separated from other unbound proteins by washing at first with 10 bed volumes of wash 
buffer (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, pH 8.0), followed by wash 
with 10 bed volumes wash buffer. Proteins were then eluted with a buffer containing 50 
mM NaH2PO4, 300 mM NaCl, 500 mM Imidazole, pH 8.0 in 1-2 mL fractions. Protein 
concentration of each fraction was determined by Bio-Rad protein assay (Bio-Rad USA) 
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4.2.6.2 GSH column 
 The GST tagged proteins were purified using GSH resin (Amersham). The 






O, 100 mM NaCl, 
0.1 % v/v Tween-20, 1 mM EDTA, 1 mM DTT at pH 7.5) was added followed by the 
addition of Lysozyme (Sigma) at 1 mg/mL and incubation was continued on ice for 30 
min. A 20X concentration was performed, e.g. 200 mL starting culture volume is 
concentrated to 10 mL lysis buffer. The cells were sonicated for further lysis. Sonication 
was carried out with 30 % amplitude, 10 sec ON, 10 sec OFF, using the SONICS
™ 
(Newtown, CT, USA) VIBRA CELL. The lysed cells were then centrifuged at 13,000 
rpm for 30 min at 4 °C. The supernatant was incubated with 500 μL GSH beads / 100 
mL culture, for 1hr at 4 °C. The GST tagged proteins were separated from other 
unbound proteins by washing at with 10 bed volumes of wash buffer (137 mM NaCl, 3 








at pH 7.4 with HCL). Elution of the GST 
tagged proteins was done by the addition of elution buffer (10 mM Tris, 50 mM GSH). 
Elution of the proteins was monitored using the Bio-Rad protein assay. Proteins were 
then eluted with a buffer containing 50 mM NaH2PO4, 300 mM NaCl, 500 mM 
Imidazole, pH 8.0 in 2 mL fractions. Protein concentration of each fraction was 
determined by Bio-Rad protein assay (Bio-Rad USA) and the purity of the eluents was 
analyzed using 10% SDS-PAGE Gel.  
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4.2.7 Cell-Culture conditions and transfection experiment using 
Lipofectamine 2000. 
MCF7 cells were grown in DMEM (Invitrogen, Carlsbad, CA) containing 10% 
fetal bovine serum (FBS; Gibco Invitrogen), 100 UmLpenicillin, and 100 mg/mL 
streptomycin (Thermo Scientific, Rockford, IL). The cells were maintained in a 
humidified 378C incubator with 5% CO2. MCF7 cells were seeded on sterile 12-mm 
glass coverslip contained in 24-well plates and left to adhere and grow to cell confluency 
of 80%-90% per well prior to transfection in order to obtain high efficiency in 
expression levels, and to minimize decreased cell growth associated with high 
transfection activity. The ratio of DNA (in µg) to Lipofectamine 2000 (in µl) used when 
preparing complexes, was 1µg plasmid: 2µL Lipofectamine 2000. Antibiotics were not 
mixed into growth media during transfection as this will cause cell death. Dilute DNA 
was diluted in 50 μL of Opti-MEM® I Reduced Serum Medium without serum and 
gently mixed. Lipofectamine 2000 was diluted into 50 μL of Opti-MEM® I Medium 
(without serum). The mixture was gently mixed and was incubated for 5 minutes at 
room temperature. Longer incubation times may decrease activity. After the 5 minute 
incubation, the diluted DNA was combined with the diluted Lipofectamine 2000 to a 
total of 100 μL reaction volume. The reaction was gently mixed and incubated for 20 
minutes at room temperature to allow the formation of DNA-Lipofectamine 2000 
complexes. The DNA-Lipofectamine 2000 complexes were stable for up to 6 hours at 
room temperature. 100 μL of DNA-Lipofectamine 2000 complexes was added into each 
well containing cells and medium. The plate was gently mixed by rocking back and 
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forth. The cells were incubated at 37°C in a CO2 incubator for 24-48 hours until they 
were ready imaging experiment. Growth medium was replaced after 4-6 hours. 
 
 
4.2.8 Immuno-Fluorescence using c-Src pY416 pY527. 
MCF7 cells were seeded on sterile 12-mm glass coverslips contained in 24-well 
plates and left to adhere for 24 h prior to transfection.MCF7 cells were fixed using 3.8% 
formaldehyde for 20 minutes. Next, the cells were permeabilized using 0.2%Triton X-
100 for 10 minutes. The cells were then blocked with 3%BSA. Next, the cells were 
incubated with 1:100 ratio of 100uL anti c-Src, anti-pY416 or anti-pY527 for 2hr. Next, 
the cells were washed twice using 300uL of 1XPBS. The cells were then incubated with 
appropriate secondary antibody 1:100 ratio of Anti-mouse TR or 1:100 ratio of anti-
rabbit TR. The cells were again washed twice with 300uL of 1XPBS. Next, the cells 
were incubated with 10uM of PTP1B mutant labeled with 4-Fluoro-7-
sulfamoylbenzofurazan-ABDF. Next, the mammalian cells were viewed under DIC, 
RFP filter set (Ex BP535– 555HQ, dichroic DM565, Em 570–625HQ) and ABDF filter 
set (Ex BP360–370, dichroic DM400, Em BA528). Images were acquired using 
Observer Z1 (Zeiss, Germany) equipped with a 63X NA1.4 objective and a CoolSNAP 
HQ2 CCD camera (Photometrics, USA). All images were processed by using the 
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4.2.9 H2O2 stimulation experiment on c-Src transfected CHOK cells, 
confirmed by Immuno-Fluorescence using anti- pY416. 
 
CHOK cells were seeded on sterile 12-mm glass coverslips contained in 24-well 
plates and left to adhere for 24 h prior to transfection. CHOK cells were transfected with 
w/t c-Src for 48 hours. After 48 hours, the cells were stimulated with 5mM of H2O2. An 
increase in Y416 phosphorylation should be observed. The cells were then immediately 
fixed using 3.8% formaldehyde for 20 minutes. Next, the cells were permeabilized using 
0.2%Triton X-100 for 10 minutes. The cells were then blocked with 3%BSA. Next, the 
cells were incubated with 1:100 ration of 100uL anti-pY416 for 2hr. Next, the cells were 
washed twice using 300uL of 1XPBS. The cells were then incubated with 1:100 ratio of 
Anti-rabbit TR. The cells were again washed twice with 300uL of 1XPBS. Next, the 
cells were incubated with 10uM of PTP1B mutant labeled with ABDF. Images were 
acquired using Observer Z1 (Zeiss, Germany) equipped with a 63X NA1.4 objective and 
a CoolSNAP HQ2 CCD camera (Photometrics, USA). All images were processed by 
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4.2.10 Western Blotting for detecting C-Src Tyrosine Kinase using anti-
pY416 and anti-pY527. 
  
To monitor the effects of c-Src tyrosine activity via the phosphorylation effect of 
Y416 and Y527, samples (purified protein and mammalian cell lysate) were separated 
on 12% SDS/PAGE gel and further transferred to PVDF membranes. Membranes were 
blocked with 5% BSA in 1XTBS. After blocking, membranes were incubated with, anti-
c-Src (from CalBiochem, 1/3000), anti-pY416 (from Cell Signaling, 1/1000) or anti-
pY527 (from Cell Signaling, 1/1000). After incubation, membranes were washed with 
1XTBST for three times and then incubated with an appropriate secondary antibody 
[anti-mouse conjugated HRP (1/5000) or anti-rabbit conjugated HRP (1/5000)]. After 
secondary incubation, blots were washed again with 1XTBST before the development 
with SuperSignal West Pico kit (from Pierce).  
 
4.2.11 Labeling PTP1B with 4-Fluoro-7-sulfamoylbenzofurazan-ABDF 
PTP1B STM (Cysteine Serine) and PTP1B double mutants were expressed 
and purified and exchanged into 100 mM Tris (pH 7.0) using FPLC. The PTP1B was 
then reacted with excess ABDF dissolved in DMSO. 26 µM PTP1B was labeled with 
500 µM ABDF for 1 hour. After 1 hour, excess ABDF was immediately removed using 
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4.3 Chapter 3 
4.3.1 General 
Human ORFeome entry clones were purchased from Open Biosystem and 
Gateway Destination Vector from Invitrogen. All enzymes used in this LR reaction, LR 
clonase, proteinase K were purchased from Invitrogen. The transfection reagent 
Lipofectamine used was purchased from Invitrogen, Hoechst dye (33342) was purchased 
from Molecular probes. 
 
4.3.2 LR reaction  
The perform  LR reaction,  300ng of pCDNA-Dest47/53 was added  into 1.6uL of 5 X 
LR Buffer, 1.0uL of 1 X TE Buffer and 4.0uL of Miniprep entry clone plasmid to a total 
of 8.0uL reaction mix.  The reaction was set on 96-well PCR plate/ tubes. The 
plate/tubes were incubated @ 25°C overnight. After 16 hrs, 0.5uL proteinase K was 
added into the plate @ 37°C for 1hr. The plate/ tubes were placed in 4°C. The entire mix 
was used for transformation into TOP10 cells and plated on 6-well plate. To insert genes 
into gateway destination vectors, primers were designed that flank the gene of interest, 











Figure 4.2 The LR cloning reaction facilitates recombination of an attL substrate (entry 
clone) with an attR substrate (destination vector) to create an attB-containing expression 
clone. This reaction is catalyzed by LR Clonase enzyme mix. New site formed is called 
a B site in the expression clone, and a P site in the by product. L1 and L2 were cut to 
form sticky ends by the Gateway recombination proteins. These sticky ends will later 
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4.3.3 Colony PCR 
 
 Colony PCR was performed to verify the LR recombinant based on ORF size 
using the primers of pCDNA-Dest47/53 below: 
AttB1 5’ ACAAGTTTGTACAAAAAAGCAGGC 3’  
AttB2 5’ ACCCAGCTTTCTTGTACA3’ 
For multiple samples, a large master mix of the followings was made on ice and 
aliquoted 50 μL in 96-well PCR tube: 38 μL sterile distilled water, 5 μL 10X PCR buffer 
(500 mM KCl, 100 mM Tris-HCl (pH 9.0), 1.0% Triton X 100), 3 μL 25 mM MgCl2, 1 
μL 10 mM, dNTPs (10 mM each dATP, dTTP, dGTP. dCTP), 1 μL 20 μM forward 
primer, 1 μL 20 μL reverse primer, 0.2-1 μL Taq polymerase. A small amount of the 
colony was scribed using yellow tip and added into each cold PCR tube containing the 
PCR reaction. The mixture was pipetted up and down for homogeneous mixture. 
Sufficient mixing would result in complete cell lysis and high yields.  
PCR conditions used were as following:  
1 cycle 5 min at 95°C – for the initial cell breakage and DNA denaturation 
1 min at 95°C – to denature DNA into single strands 
30-40 cycles 1.5 min at 54X°C - temperature depends on primers) 
1 min at 72°C –for primer primes extension from 3'-end by Taq (1 min/kb) 
1 cycle 5 min at 72°C – for final extension to make sure all products were full length 
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4.3.4 Transfect the transformed plasmid into mammalian cells to 
monitor in vivo phosphatase localization. 
 
HEK293T cells were seeded in 96-well sterile plate. The transfection reaction 
was carried out after 2 days when the cells confluency to reached 80%. The RPMI 
medium used was at 500uL /well. For transfection reaction to be carried out, 1ug 
plasmid premixed with 25uLRPMI is added into 2.5uL Lipofectamine premixed 
with 22.5uL RPMI.  Note that this was a single reaction for 1 entry clone plasmid. Final 
volume of 50uL reaction was incubated in eppendorf tube at RT for 20 minutes. After 20 
minutes, 50uL reaction was then pipette into each well of 96-well plate. Note that 96 
well plate will require 96 different sets of transfection reaction from 96 different 
phosphatase entry clones. . The cells were incubated at 37°C in a CO2 incubator for 24-
48 hours until they were ready imaging experiment. Growth medium was replaced after 
4-6 hours. After 24 hours, the mammalian cells were viewed under DIC, RFP filter set 
(Ex BP535– 555HQ, dichroic DM565, Em 570–625HQ) and Dapi filter set (Ex BP360–
370, dichroic DM400, Em BA520). Images were acquired using Observer Z1 (Zeiss, 
Germany) equipped with a 63X NA1.4 objective and a CoolSNAP HQ2 CCD camera 
(Photometrics, USA). All images were processed by using the MetaMorph software 
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6.1 Supplemental Tables 










1 8622 246 A1 Cytoplasm Nucleus Dual specificity phosphatase 22   Miniprep Miniprep Miniprep 
2 10147 435 A2 Nucleus Cytoplasm Dual specificity phosphatase 3 (vaccinia virus 
phosphatase VH1-related)   
Miniprep Miniprep Miniprep 
3 2039 654 A3 Cytoplasm  Dual specificity phosphatase 19   Miniprep Miniprep Miniprep 
4 8591 678 A4 Nucleus  Protein phosphatase 2A 48 kDa regulatory 
subunit   
Miniprep Miniprep Miniprep 
5 1089 930 A5 Cytoplasm Nucleus Protein phosphatase 2 (formerly 2A), catalytic 
subunit, beta isoform   
Miniprep Miniprep Miniprep 
6 3745 1200 A6 Cytoplasm Plsma 
membrane 
Protein tyrosine phosphatase, non-receptor type 
7, transcript variant 2   
Miniprep Miniprep Miniprep 
7 6062 1179 A7 Cytoplasm Nucelus Integrin-linked kinase-associated 
serine/threonine phosphatase 2C, transcript 
variant 1   
Miniprep Miniprep Miniprep 




Hypothetical protein FLJ22405   Miniprep Miniprep Miniprep 
9 641 2115 A9 Cytoplasm  Myotubularin related protein 8   Miniprep Miniprep Miniprep 
10 9013 267 A10 ER  Epilepsy, progressive myoclonus type 2A, 
Lafora disease (laforin)   
Miniprep Miniprep Miniprep 
  115 
11 7420 318 A11 Mitochondria Cytoplasm, 
Cytosol 
Cytochrome c, somatic   Miniprep Miniprep Miniprep 





Protein tyrosine phosphatase type IVA, member 
3, transcript variant 2   
Miniprep Miniprep Miniprep 
13 9048 537 B1 Cytoplasm  Slingshot 2   Miniprep Miniprep Miniprep 
14 6314 597 B2 Cytoplasm  Dual specificity phosphatase 13   Miniprep Miniprep Miniprep 
15 4071 930 B3 Cytoplasm Chromosome Protein phosphatase 2 (formerly 2A), catalytic 
subunit, alpha isoform   
Miniprep Miniprep Miniprep 
16 7603 1155 B4 Chromosome  Protein phosphatase 2, regulatory subunit B 
(B56), gamma isoform, transcript variant 4   
Miniprep Miniprep Miniprep 
17 3508 1641 B5 Nucleoplasm Cytoplasm Protein phosphatase 1G (formerly 2C), 
magnesium-dependent, gamma isoform, 
transcript variant 1   
Miniprep Miniprep Miniprep 
18 3670 453 B6 Cytoplasm Nucleulos, 
Cytosol 
Hypothetical protein FLJ20442   Miniprep Miniprep Miniprep 
19 8740 579 B7 Cyoplam  Protein phosphatase 1B (formerly 2C), 
magnesium-dependent, beta isoform, transcript 
variant 3   
Miniprep Miniprep Miniprep 
20 8800 531 B8 Nucleus  Protein phosphatase 2A 48 kDa regulatory 
subunit   
Miniprep Miniprep Miniprep 
21 3126 597 B9 Cytoplasm Nucleus Dual specificity phosphatase 14   Miniprep Miniprep Miniprep 
22 3671 636 B10  Golgi, 
Nucleus 
Hypothetical protein MGC1136   Miniprep Miniprep Miniprep 
23 6324 954 B11 Cytoplasm  Protein phosphatase 1, regulatory (inhibitor) 
subunit 3C   
Miniprep Miniprep Miniprep 
24 6656 936 B12 Plasma 
membrane 
 Phosphatidic acid phosphatase type 2B, 
transcript variant 1   
Miniprep Miniprep Miniprep 
25 7076 972 C1 Nucleus Cytoplasm, 
nucleolus 
Protein phosphatase 1, catalytic subunit, gamma 
isoform   
Miniprep Miniprep Miniprep 
26 7862 963 C2 Cytoplasm  Dual specificity phosphatase 7   Miniprep Miniprep Miniprep 
  116 
27 882 1086 C3 Cytoplasm    Miniprep Miniprep Miniprep 
28 7554 1062 C4 ER Nucleus, 
Cytoplasm 
Protein tyrosine phosphatase, non-receptor type 
2, transcript variant 3   
Miniprep Miniprep Miniprep 
29 5095 1146 C5 Cytoplasm Nucleus Dual specificity phosphatase 6, transcript 
variant 1   
Miniprep Miniprep Miniprep 
30 5861 1770 C6 Cytoplasm Chromosome, 
membrane 
fraction 
Protein phosphatase 2 (formerly 2A), regulatory 
subunit A (PR 65), alpha isoform   
Miniprep Miniprep Miniprep 
31 1551 2004 C7 Cytoplasm Nucleus, 
membrane 
fraction 
Protein phosphatase 2 (formerly 2A), regulatory 
subunit A (PR 65), beta isoform, transcript 
variant 2   
Miniprep Miniprep Miniprep 
32 2100 1962 C8   Protein phosphatase, EF hand calcium-binding 
domain 1, transcript variant 1   
Miniprep Miniprep Miniprep 
33 5606 318 C9 Mitochondria Cytoplasm, 
Cytosol 
Cytochrome c, somatic   Miniprep Miniprep Miniprep 
34 8056 378 C10 Cytoplasm  Phosphohistidine phosphatase 1   Miniprep Miniprep Miniprep 
35 8703 387 C11 Plasma 
membrane 
 Protein tyrosine phosphatase, receptor type, S   Miniprep Miniprep Miniprep 
36 8316 513 C12 Cytoplasm Nucleus, 
plasma 
membrane 
Protein phosphatase 3 (formerly 2B), regulatory 
subunit B, 19kDa, alpha isoform (calcineurin B, 
type I)   
Miniprep Miniprep Miniprep 
37 159 744 D1 Nucleus  Likely ortholog of mouse protein phosphatase 
2C eta   
Miniprep Miniprep Miniprep 




Phosphatidic acid phosphatase type 2C, 
transcript variant 1   
Miniprep Miniprep Miniprep 
39 6415 867 D3  Cytoplasm, 
ER 
Protein tyrosine phosphatase-like (proline 
instead of catalytic arginine), member a   
Miniprep Miniprep Miniprep 
40 5533 918 D4 Nucleus  Protein phosphatase 6, catalytic subunit   Miniprep Miniprep Miniprep 
41 7929 924 D5 Nucleus Centrosome, 
Cytoplasm 
Protein phosphatase 4 (formerly X), catalytic 
subunit   
Miniprep Miniprep Miniprep 
42 88 957 D6 Nucleus  Hypothetical protein MGC10067   Miniprep Miniprep Miniprep 
43 3788 993 D7 Cytosketelon Nucleolus Protein phosphatase 1, catalytic subunit, alpha 
isoform   
Miniprep Miniprep Miniprep 
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44 4085 984 D8 Nucleolus  Protein phosphatase 1, catalytic subunit, beta 
isoform   
Miniprep Miniprep Miniprep 
45 4668 993 D9 Nucleus Nucleolus Dual specificity phosphatase 11 (RNA/RNP 
complex 1-interacting)   
Miniprep Miniprep Miniprep 
46 4719 1026 D10 Cytoplasm Nucleus Slingshot 3   Miniprep Miniprep Miniprep 
47 4859 1023 D11 Nucleus Cytoplasm Dual specificity phosphatase 12   Miniprep Miniprep Miniprep 
48 2025 1110 D12 Plasma 
membrane 
 Phosphatase and tensin homolog (mutated in 
multiple advanced cancers 1), pseudogene 1   
Miniprep Miniprep Miniprep 
49 9757 1119 E1   Hypothetical protein DKFZp761G058   Miniprep Miniprep Miniprep 
50 2502 1149 E2   Protein phosphatase 1A (formerly 2C), 
magnesium-dependent, alpha isoform, transcript 
variant 1   
Miniprep Miniprep Miniprep 
51 3809 1146 E3   Dual specificity phosphatase 6, transcript 
variant 1   
Miniprep Miniprep Miniprep 
52 5798 1161 E4   Acid phosphatase, prostate   Miniprep Miniprep Miniprep 
53 4057 1185 E5   Dual specificity phosphatase 4, transcript 
variant 1   
Miniprep Miniprep Miniprep 
54 1776 1293 E6   Protein phosphatase 2 (formerly 2A), regulatory 
subunit B (PR 52), gamma isoform   
Miniprep Miniprep Miniprep 
55 2939 1308 E7   Protein tyrosine phosphatase, non-receptor type 
1   
Miniprep Miniprep Miniprep 
56 8117 1332 E8   Protein phosphatase 2 (formerly 2A), regulatory 
subunit B (PR 52), beta isoform, transcript 
variant 2   
Miniprep Miniprep Miniprep 
57 2863 1383 E9   Protein tyrosine phosphatase, non-receptor type 
11 (Noonan syndrome 1)   
Miniprep Miniprep Miniprep 
58 7841 1422 E10   Cell division cycle 25C, transcript variant 1   Miniprep Miniprep Miniprep 
59 8448 1449 E11   Dual specificity phosphatase 10, transcript 
variant 1   
Miniprep Miniprep Miniprep 
60 8407 1536 E12   Protein phosphatase 3 (formerly 2B), catalytic 
subunit, alpha isoform (calcineurin A alpha)   
Miniprep Miniprep Miniprep 
  118 
61 4501 1575 F1   Cell division cycle 25A   Miniprep     
62 N/A   N/A   N/A     N/A  N/A      
63 4946 1776 F3   Protein tyrosine phosphatase, receptor type, N   Miniprep     
64 2573 2382 F4   Protein tyrosine phosphatase, receptor type, A, 
transcript variant 2   
Miniprep     
65 2020 474 F5   DKFZP566K0524 protein   Miniprep     
66 4644 477 F6   Acid phosphatase 1, soluble, transcript variant 2 
  
Miniprep     
67 4051 558 F7   Dual specificity phosphatase 3 (vaccinia virus 
phosphatase VH1-related)   
Miniprep     
68 966 1620 F8   Lymphocyte-specific protein tyrosine kinase   Miniprep     
69 4334 1539 F9   Protein phosphatase 3 (formerly 2B), catalytic 
subunit, gamma isoform (calcineurin A gamma) 
  
Miniprep     
70 4872 1545 F10   Eyes absent homolog 2 (Drosophila), transcript 
variant 5   
Miniprep     
71 9578 1590 F11   Pyruvate dehydrogenase phosphatase isoenzyme 
2   
Miniprep     
72 95 1782 F12   Protein tyrosine phosphatase, non-receptor type 
9   
Miniprep     
73 845 1794 G1   RNA guanylyltransferase and 5'-phosphatase   Miniprep     
74 1447 1812 G2   Myotubular myopathy 1   Miniprep     
75 4543 1794 G3   Protein tyrosine phosphatase, non-receptor type 
6, transcript variant 2   
Miniprep     
76 10203 1953 G4   Hypothetical protein FLJ22405   Miniprep     
77 2960 2781 G5   Protein tyrosine phosphatase, non-receptor type 
4 (megakaryocyte)   
Miniprep     
78 3032 2541 G6   Discs, large homolog 7 (Drosophila)   Miniprep     
79 5976 2541 G7   Discs, large homolog 7 (Drosophila)   Miniprep     
  119 
80 9933 3588 G8     Myotubularin related protein 4   Miniprep     
81 10144 3555 G9     Cartilage intermediate layer protein, nucleotide 
pyrophosphohydrolase   
Miniprep     
82 838 1818 G10     Protein phosphatase 1D magnesium-dependent, 
delta isoform   
Miniprep     
83 2024 1602 G11     Transmembrane phosphatase with tensin 
homology, transcript variant 2   
Miniprep     
84 10312 1866 G12     Myotubularin related protein 6   Miniprep     
85 10667 2103 H1     Protein tyrosine phosphatase, receptor type, E   Miniprep     
86 11227 1611 H2     Eyes absent homolog 3 (Drosophila)   Miniprep     
87 10846 2802 H3     Protein phosphatase 4, regulatory subunit 1   Miniprep     
88 11351 1989 H4     Dual specificity phosphatase 16   Miniprep     
89 11706 1515 H5     Mitogen-activated protein kinase 7 interacting 
protein 1, transcript variant alpha   
Miniprep     
90 11764 1797 H6     Hypothetical protein FLJ22405   Miniprep     
91 11976 708 H7     Dual specificity phosphatase-like 15, transcript 
variant 1   
Miniprep     
92 12272 816 H8       Miniprep     
93 12358 519 H9     Cyclin-dependent kinase inhibitor 3 (CDK2-
associated dual specificity phosphatase)   
Miniprep     
94 12005 1698 H10     Protein tyrosine phosphatase, non-receptor type 
5 (striatum-enriched)   
Miniprep     
95 12408 522 H11     Protein tyrosine phosphatase type IVA, member 
1   
Miniprep     
96 12482 555 H12     Dual specificity phosphatase 22   Miniprep     
97 13025 213 A1     Acid phosphatase 1, soluble         
98 12889 540 A2     Protein tyrosine phosphatase, non-receptor type 
22 (lymphoid)   
      
99 13237 1794 A3     Protein tyrosine phosphatase, receptor type, O         
100 13368 339 A4             
  120 
101 13687 531 A5     Hypothetical protein MGC5987         
102 13625 1056 A6     Protein tyrosine phosphatase, non-receptor type 
18 (brain-derived)   
      
103 13596 1344 A7     Protein phosphatase 2 (formerly 2A), regulatory 
subunit B (PR 52), alpha isoform   
      
104 13613 1851 A8     Eyes absent homolog 4 (Drosophila)         
105 13659 2316 A9             
106 15047 1164 A10     Protein tyrosine phosphatase, non-receptor type 
2, transcript variant 2, mRNA (cDNA clone 
MGC: 9389 IMAGE:3872164), complete cds.   
      
107 14140 1362 A11     Protein phosphatase 2, regulatory subunit B, 
delta isoform, transcript variant 1, mRNA 
(cDNA clone MGC: 51327 IMAGE: 5267510), 
complete cds.   
      
108 14165 1062 A12     Protein tyrosine phosphatase, receptor type, F, 
mRNA (cDNA clone IMAGE: 5303842), 
complete cds.   
      
109 14212 234 B1     cDNA clone MGC: 75444 IMAGE:4753885, 
complete cds.   
      
110 14329 1449 B2     Dual specificity phosphatase 10, transcript 
variant 1, mRNA (cDNA clone MGC: 74610 
IMAGE: 6178330), complete cds.   
      
111 14428 1752 B3     Protein tyrosine phosphatase, non-receptor type 
9, mRNA (cDNA clone MGC: 87169 IMAGE: 
5276190), complete cds.   
      
112 14725 1044 B4     Protein tyrosine phosphatase, receptor type, F, 
mRNA (cDNA clone IMAGE: 4661274), 
complete cds.   
      
113 14960 423 B5     cDNA clone MGC: 88825 IMAGE: 4896064, 
complete cds.   
      
114 14912 753 B6     Tensin-like SH2 domain containing 1, mRNA 
(cDNA clone IMAGE: 4611842), complete cds. 
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115 14941 504 B7     Protein tyrosine phosphatase type IVA, member 
2, transcript variant 1, mRNA (cDNA clone 
MGC: 88163 IMAGE: 4686913), complete cds. 
  
      
116 14954 1251 B9     Tensin, mRNA (cDNA clone IMAGE: 
4878104), complete cds.   
      
117 2715 1500 B10     Protein phosphatase 5, catalytic subunit         
118 7390 1161 B11     Acid phosphatase, prostate         
119 4352 1734 B12     Protein tyrosine phosphatase, non-receptor type 
23   
      
  122 
6.2 Supplemental Figures 
6.2.1 Vector Information- pcDNA-DEST47 
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6.2.1 Vector Information- pcDNA-DEST53 
 
 
